




INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁴ :	A1	(11) International Publication Number:	WO 86/05519
C12Q 1/68, C12P 19/34		(43) International Publication Date:	25 September 1986 (25.09.86)
C12N 15/00			
(21) International Application Number:	PCT/US86/00545	(81) Designated States:	AT (European patent), AU, BE (European patent), CH (European patent), DE (European patent), FR (European patent), GB (European patent), IT (European patent), JP, LU (European patent), NL (European patent), SE (European patent).
(22) International Filing Date:	14 March 1986 (14.03.86)		
(31) Priority Application Number:	712,396	Published	<i>With international search report.</i>
(32) Priority Date:	15 March 1985 (15.03.85)		
(33) Priority Country:	US		
(71)(72) Applicant and Inventor:	SUMMERTON, James [US/US]; 990 Southeast Marion Street, Corvallis, OR 97333 (US).		
(74) Agents:	DEHLINGER, Peter, J. et al.; Ciotti & Murrashige, 545 Middlefield Road, Suite 200, Menlo Park, CA 94025-3471 (US).		

(54) Title: POLYNUCLEOTIDE ASSAY REAGENT AND METHOD



(57) Abstract

A diagnostic reagent and system for determination of a single-stranded polynucleotide analyte having a selected target sequence. The reagent includes a solid support and multiple support-bound polymers designed to bind specifically to the analyte. Each polymer is composed of a sequence of base-complementary recognition moieties which can bind specifically to corresponding in-sequence bases in the analyte target sequence, and an unbranched, stereoregular backbone whose charge density is substantially less than that of the polynucleotide analyte. A reporter in the system contains a polycationic tail adapted to bind to the analyte, under conditions in which the reporter does not bind to the less densely charged polymers, and reporter groups by which the presence of the reporter can be detected.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GA	Gabon	MR	Mauritania
AU	Australia	GB	United Kingdom	MW	Malawi
BB	Barbados	HU	Hungary	NL	Netherlands
BE	Belgium	IT	Italy	NO	Norway
BG	Bulgaria	JP	Japan	RO	Romania
BR	Brazil	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	LI	Liechtenstein	SN	Senegal
CH	Switzerland	LK	Sri Lanka	SU	Soviet Union
CM	Cameroon	LU	Luxembourg	TD	Chad
DE	Germany, Federal Republic of	MC	Monaco	TG	Togo
DK	Denmark	MG	Madagascar	US	United States of America
FI	Finland	ML	Mali		
FR	France				

POLYNUCLEOTIDE ASSAY REAGENT AND METHOD

1. Field of the Invention

The present invention relates to a
5 polynucleotide diagnostic system and method.

2. Background

Two general types of polynucleotide diagnostic systems, both based on hybridization between
10 complementary segments of a polynucleotide probe and a single-strand polynucleotide analyte, have been developed. In the first type, the polynucleotide analyte is made single stranded and fixed to a solid support, such as a nitrocellulose filter. The support
15 is then reacted, under complementary-strand annealing conditions, with a reporter-labeled probe which is complementary to a target base-sequence region of the analyte. After washing several times to remove unbound probe, the solid support is analyzed for the presence of
20 reporter. This system has not been entirely satisfactory, particularly in clinical situations, where assay simplicity and sensitivity are required. The procedure used in fixing single-strand polynucleotide material to the solid support is somewhat involved and
25 time consuming. The sensitivity of the system is limited because, in the usual case, each analyte molecule hybridizes with a single probe molecule and each probe generally contains roughly one hundred reporter moieties.

30 A second type of polynucleotide diagnostic system involves two analyte-specific probes which are each complementary to a distinct region of the analyte polynucleotide. The first probe is linked to a solid support, and the second probe is free in solution and

carries multiple reporter molecules. In practice, the analyte is mixed with the two probes under conditions which allow annealing of complementary polynucleotide strands, including annealing of both the immobilized and 5 reporter-carrying probes to the polynucleotide analyte, to attach the reporter to the solid support by means of the analyte.

Although the dual-probe system avoids the problem of having to fix the test nucleic acid material 10 to a solid support, nevertheless, the method has a number of limitations. First, when the test nucleic acid is derived from duplex nucleic acid, as is often the case, hybridization between the analyte polynucleotide and its complementary strand competes 15 with the hybridization between the analyte and the two probes. Further, since the two-probe system relies on higher order kinetics than is the case for single-probe systems, it is inherently slower than a single-probe system. Also, the need for two different probes 20 increases the cost of the system. Finally, in terms of test sensitivity, the dual-probe system suffers the same limitation as the single-probe system mentioned above--each analyte polynucleotide binds only one "reporter" probe.

25

3. Summary of the Invention

It is a general object of the invention to provide, for use in detecting a polynucleotide, a diagnostic system and method that substantially overcome 30 above-discussed problems and limitations associated with the prior art.

It is another object of the invention to provide, in such a system, a reagent having a polynucleotide-binding polymer adapted to form a

-3-

base-specific duplex structure with a single-stranded polynucleotide analyte, under conditions in which complementary polynucleotide strands remain in the single-stranded state. The analyte binding can
5 therefore be performed under conditions in which sequence-specific pairing between the reagent polymer and analyte occurs without competition from analyte-complementary strand annealing in the assay reaction mixture.

10 It is another object of the invention to provide in such a system, a reporter adapted to bind by electrostatic forces to the backbone of an analyte polynucleotide, under conditions in which reporter binding to the reagent polymer does not occur. The
15 system therefore has the capacity for very high signal levels by virtue of the relatively large number of reporter molecules which can combine with each polynucleotide analyte molecule.

Providing a polynucleotide diagnostic method
20 which is rapid, convenient, and sensitive is yet another object of the invention.

The invention includes a diagnostic reagent for use in detecting an analyte polynucleotide having a defined target base sequence. The reagent comprises a
25 solid support, and linked to the support, multiple polynucleotide-binding polymers. Each polymer is composed of a sequence of base-complementary recognition moieties, each of which is adapted to hydrogen bond to corresponding, in-sequence base of the target region of
30 the analyte, under selected binding conditions, and an unbranched, substantially stereoregular backbone (1) supporting the recognition moieties at positions which allow hydrogen bonding between the recognition moieties and the corresponding in-sequence bases of the target,

and (2) having a backbone charge density which is substantially less than that of the analyte under the selected binding conditions. In a preferred embodiment of the invention, the recognition moieties include 5 purine and pyrimidine bases and the backbone is composed of a series of backbone moieties joined by achiral, predominantly uncharged linkages. In another embodiment of the invention, the same recognition moieties are carried on a backbone whose linkages include uncharged, 10 stereoisomerically defined or achiral linkages alternating with negatively charged, achiral linkages.

A diagnostic system for detecting a polynucleotide analyte having a defined target sequence includes the diagnostic reagent and a reporter having a 15 polycationic tail adapted to bind by electrostatic attraction to the charged backbone of the polynucleotide analyte, but not to the substantially less charged, or uncharged, backbone of the reagent polymers under preselected binding conditions. One or more reporter 20 groups attached to the polycationic tail are adapted to produce a signal by which the presence of the reporter can be detected.

In the method of the invention, the polynucleotide analyte is added to the diagnostic 25 reagent under conditions in which the analyte is in a single-strand form and which allow sequence-specific pairing between the analyte and the reagent polymers. After the analyte/polymer annealing reaction, the reagent is washed to remove unbound test material. The 30 reagent and bound analyte are then reacted with the reporter, under preselected conditions in which the polycationic tail in the reporter binds electrostatically to the charged backbone of the polynucleotide but not to the substantially less charged or uncharged

-5-

backbone of the reagent polymers. The reagent is again washed to remove unbound reporter. The presence and/or amount of analyte bound to the reagent is determined in situ by measuring the reporter signal associated with 5 the reagent-bound analyte, or the reporter is eluted from the reagent/analyte and the reporter signal in the eluate is measured.

These and other objects and features of the present invention will become more fully apparent when 10 the following detailed description of the invention is read in conjunction with the accompanying figures.

Brief Description of the Figures

Figure 1 shows preferred purine and pyrimidine 15 structures used in forming polymer molecules of the invention;

Figure 2 shows preferred purine-like and pyrimidine-like recognition moieties used in forming the polymer molecules;

20 Figure 3 shows preferred cyclic backbone moieties used in forming the polymer molecules;

Figure 4 shows preferred acyclic backbone moieties used in forming the polymer molecules;

Figures 5A and 5B illustrate two preferred 25 subunit assembly schemes for coupling N₁--N₂ type subunit backbones;

Figure 6 shows the backbone structures of subunit dimers A-A through D-D formed in accordance with the methods illustrated in Figures 5A and 5B, and two 30 cyclic backbone structures formed in accordance with the methods illustrated in Figures 7A and 7B;

Figures 7A-7C illustrate three preferred subunit assembly schemes for coupling N₁--E type subunit backbones; and

-6-

Figure 8 shows preferred acyclic backbone structures of subunit dimers formed in accordance with the methods illustrated in Figures 7A-7C; and

5 Figure 9 shows the synthesis of a tetranucleotide analog having methylphosphonate backbone linkages alternating with a phosphotriester linkage;

Figure 10 illustrates reactions for attaching spacer-arm molecules to a solid support;

10 Figure 11 shows a general method for synthesis of polyamines from N-methyl amino acids;

Figure 12 shows a method for synthesis of polyamines having a terminal primary amino group;

15 Figure 13 shows the preparation of the quaternary ammonium cationic tail having a terminal primary amino group;

Figure 14 illustrates a reaction for preparing a multi-charge enzymatic reporter according to an embodiment of the invention;

20 Figure 15 illustrates a reaction for preparing a two-charge fluorescent reporter according to an embodiment of the invention; and


Figure 16 illustrates various components involved in the diagnostic system and method of the invention.

25

Detailed Description of the Invention

The diagnostic system of the invention includes a solid support reagent composed of a solid support carrying a plurality of nucleotide-binding polymer molecules. The polymeric composition of the invention is designed to bind, with a selected binding affinity, to a polynucleotide containing a target sequence of bases. The composition is composed of

non-homopolymeric, substantially stereoregular molecules or species of the form:



- where $B-R_i$ are a series of base-specific subunits containing a backbone moiety B and a recognition moiety R_i which is selected to bind specifically by Watson/Crick base pairing to a corresponding, in-sequence base in the target sequence, and the subunits are joined through their backbone moieties predominantly achiral, substantially uncharged bonds.
- 15 The design and selection of suitable subunits for use in constructing the polymer species will be described in Section I below. Methods for coupling subunits through achiral linkages are described in Section III, with subunit-protective group strategies involved in subunit synthesis being discussed in Section II.

The polymer species are synthesized by sequential subunit coupling, to form polymer molecules of a selected length and sequence. As will be described in Section IV, the length of the target sequence and polymer sequence is selected to achieve a desired binding specificity. The binding affinity of the polymer for the target can be selectively varied by several strategies discussed in Section IV, including forming either three (for greater binding affinity) or two (for lesser affinity) base-paired hydrogen bonds with the corresponding target base. The resulting composition contains polymer species or molecules, all having substantially the same sequence of subunits and

substantially the same sequence of intersubunit linkage types. In functional terms, all of the polymer species have substantially the same binding affinity for the target polynucleotide. Methods for assembling the 5 polymer, once a desired subunit sequence is selected, are given in Section V.

The polymer composition is useful in a novel solid-phase diagnostic system which is described in Section VI-VII. This system is based on the binding of 10 analyte polynucleotide molecules to support-bound polymer molecules and subsequent electrostatic attachment of multiple polycationic reporter molecules to the polynucleotide, to give an amplified reporter signal for each bound analyte molecule.

15

I. Subunit Structure

A. The Recognition Moiety

The design of the subunits B-R_i which are 20 suitable for use in forming the polymer species of the invention involves a number of structural and/or stereochemical criteria which must be met both by the backbone and recognition moieties and by the linkage between the two. The design requirement of the 25 recognition moiety will be considered first.

The recognition moiety of each subunit must provide two or three hydrogen-bonding groups held in an unambiguous configuration adapted for hydrogen bonding to two or three of the Watson/Crick hydrogen bonding 30 sites on a specified in-sequence base of the target genetic sequence. To avoid undesired mispairing between recognition moiety and its corresponding target base, under the conditions of use, (1) the tautomeric state of the recognition moiety should be relatively stable, and

(2) the recognition moiety should have a structure which provides a relatively rigid arrangement of the hydrogen-bonding groups. Such rigidity is best afforded by a ring structure having the polar hydrogen-bonding groups 5 either forming part of the ring or directly attached to the ring.

The preferred recognition moiety structures include purine, purine-like, pyrimidine, and pyrimidine-like structures which are designed to form 10 Watson/Crick base pairing, through either two or three hydrogen bonds, with selected polynucleotide bases. The group of subunits used in polymer synthesis includes at least two recognition moieties which are base-specific for different polynucleotide bases, and preferably one 15 or more recognition moieties for each of the four bases in a natural DNA or RNA polynucleotide. Also, as will be seen below, it is desirable to provide one group of recognition moieties, R_i , which are capable of base-pairing with nucleotide bases through two hydrogen 20 bonds, and a second group, R_j which are capable of binding with the same bases through three hydrogen bonds. Figure 1 shows exemplary purine and pyrimidine type recognition moieties. The purine structures 1 and 2 are designed to bind to thymine or uracil bases, 25 structures 3-6, to guanine bases; structures 7-9, to cytosine bases, and structures 10-12, to adenine bases. Structures 1, 4, 5, 6, 8, and 10-12 are R_i type moieties adapted to bind to corresponding in-sequence bases through two hydrogen bonds, and the remaining 30 structures are R_j type moieties which form three hydrogen bonds on base pairing. As will be seen below, purine and pyrimidine nucleosides are useful in synthesizing a variety of other subunits which are suitable for use in polymer synthesis. These subunits,

-10-

modified if necessary with amine protective groups, can be obtained from commercial sources, or prepared according to known methods, such as those described or referenced in Example 1.

5 A number of purine-like or pyrimidine-like structures in which the recognition moiety is joined to the backbone through an annular carbon are shown in Figure 2. These structures have base pairing specificities and hydrogen bonding properties like those
10 of the analogous structures shown in Figure 1. Although the binding properties of a polymer containing a carbon-linked recognition moiety may not be significantly different from that of a polymer whose recognition moieties are nitrogen-linked, as in Figure 1,
15 subunits incorporating the carbon-linked moieties generally require a greater synthetic effort than do subunits containing preformed purine and pyrimidines. However, for some subunit syntheses, such as the synthesis of the achiral acyclic backbone subunits
20 described in Example 10, the carbon-linked recognition moieties provide a useful starting material.

B. The Backbone Moiety

The backbone moiety of each subunit has the
25 general form $N_1 --- E$, or $N_1 --- N_2$, where N_1 and N_2 are nucleophilic groups and E is an electrophilic group. Based on ease of subunit coupling and required stability of the resultant intersubunit linkage, as discussed below, the preferred nucleophilic groups are
30 amino, hydroxyl and hydrazino; and the preferred electrophilic groups, and/or electrophilic linking agents, are derivatives of carbonic, thiocarbonic, carboxylic, and sulfonic acids.

-11-

Backbone moieties can have either a cyclic or an acyclic structure. While the total number of possible backbone moiety structures is very large, nevertheless, only a rather limited number of structures 5 are of actual practical value due to a number of factors. The initial procedure by which promising backbone moieties were selected was as follows.

As a first condition, only those cyclic backbone moieties were considered which consisted of, or 10 could be readily derived from, deoxyribose or ribose. This limitation is a practical one and reflects the difficulty and corresponding greater expense of de novo synthesizing ring structures having multiple chiral centers. In general prospective backbone moieties and 15 intersubunit linkages expected to be suitable for polymers were selected on the basis of one or more of the following factors: feasibility of synthesis based on known reactions; expected ease of synthesis from available starting materials; simplicity of structure; 20 and expected stability of the final backbone.

Initial screening of promising backbone moieties and intersubunit linkages was performed as follows. Space-filling CPK molecular models of duplex DNA and RNA were constructed according to parameters 25 determined by x-ray diffraction of oligodeoxyribo nucleotides in the B-form and oligonucleotides in the A-form. In each of these constructed duplexes one of the two sugar-phosphate backbones was removed. Next, each prospective backbone was attached, if possible, to 30 the sites on the bases from which the original sugar-phosphate backbone had been removed. Each resulting polynucleotide/polymer duplex was then examined for coplanarity of the Watson/Crick base-pairs, torsional and angle strain in the prospective polymer

backbone, degree of distortion imposed on the nucleic acid strand, and interstrand and intrastrand nonbonded interactions. Special attention was paid to whether or not each amide-containing backbone could readily adopt a 5 conformation wherein its amide moieties were planar. This is important because of the substantial energy cost required to force an amide into a nonplanar conformation.

These initial studies verified that the required unit backbone length (i.e., the N₁---E 10 spacing in an N₁---E or activated N₁---N₂---E subunit) is 5-7 atoms for backbone moieties constituting or derived from deoxyribose or ribose (cyclic backbone structures), with a 6-atom length being optimal.

Subunit structure judged acceptable in the 15 above modeling studies were then assessed for feasibility of synthesis (on the basis of key synthetic reactions reported in the literature, or reactions carried out on model compounds; and/or via actual synthesis of the subunits) and stability of the 20 assembled polymer backbone (preliminary stability studies were generally carried out with suitably linked model compounds or subunit dimers). These types of studies were used to further restrict the number of candidate backbone structures. From this restricted 25 candidate pool the cyclic backbone structures A-G shown in Figure 3 were ultimately selected as preferred structures.

In this figure, subunits A-D containing N₁---N₂ type cyclic backbone moieties include: 30 2'-deoxyribonucleosides (structure A); 2'-deoxyribonucleosides substituted at the 5' and 3' positions with an amino group (structures B and C, respectively); and morpholino derivatives of 35 ribonucleosides (structure D). Subunits containing

N_1 --- E-type backbone moieties include 2'-deoxyribonucleosides substituted at their 5' positions with one and two-carbon acids (structures E and F, respectively); and N-aminomorpholino derivatives 5 of ribonucleosides substituted at their 5' positions with carboxylic acid (structure G) or sulfonic acid (structure H)

The same molecular modeling approach applied to acyclic (unbranched chain) backbone moieties showed that 10 unit backbone lengths ranging from 4-6 atoms are acceptable, in terms of polymer conformation in base-pair hydrogen bonding to single-stranded polynucleotide, with a 5-atom backbone length being optimal. This is in contrast to cyclic backbones, where 15 a 6-atom unit backbone length is optimal. Further, the modeling work showed that the annular recognition moiety cannot be directly attached to the linear backbone moiety without severely inhibiting of coplanarity of the complementary bases and introducing undesirable 20 interactions between the recognition moiety and the backbone the minimum binding strain occurred when the recognition moiety was linked to the backbone moiety by a one-atom spacer. Two-atom, but not three-atom, spacers may be tolerated, although increased degrees of 25 freedom between the recognition moieties and the linear backbone may lead to mispairing with target bases with two-atom spacers.

The acyclic backbone moiety structures I-N shown in Figure 4, all of which contain a one-atom methylene 30 spacer between the backbone and recognition moieties, gave a good modeling prediction for favorable base-pairing to a complementary polynucleotide. Analogous structures containing a two-carbon spacer showed acceptable, but less favorable, binding

conformation. The structures shown in the figure, and the analogous two-carbon spacer structures, are preferred acyclic backbone moieties because of their general ease of synthesis. It should be mentioned, 5 however, that a number of other backbone moieties are also entirely feasible and suitable -- although generally not as easy and/or inexpensive to synthesize.

C. Backbone/Recognition Moiety Linkage

As indicated above, the linkage or spacer connecting the backbone and recognition moieties in the polymer subunit must meet certain design criteria which are effective to position the recognition moieties for base-pair binding to the polynucleotide bases. In the 10 case of the cyclic backbone moieties shown in Figure 3, modeling studies indicate that the most favorable 15 binding conformation in the polymer occurs when the recognition moiety is attached directly to the 1' carbon of the ribose or ribose-like structures, and to the 20 analogous 1' position of the morpholino structures. That is, the moiety is attached at normal point of attachment and with the normal stereoisomeric configuration of purine or pyrimidine bases to the 25 ribose or deoxyribose groups of nucleosides. For the acyclic structures, one-and two-carbon atom spacers are required for placing the recognition moieties at favorable binding positions, with one-atom spacers being preferred, as discussed above.

In order to achieve a stereoregular polymer 30 configuration required for uniform binding affinity of the polymer molecules to a polynucleotide target, it is also necessary that all of the backbone/recognition moiety linkages be either of define chirality or achiral. The linkages are considered to be of defined

-15-

chirality, for purposes of definition herein, if each of the linkages in any given subunit position in all of the polymer molecules has the same stereoisomeric configuration, or chirality. That is, although the 5 subunits in different sequence positions may have different internal stereoisomer configurations (including achirality at specific sequence positions), all of the linkages at a given sequence position among the polymer molecules have the same stereoisomeric 10 configuration. Usually defined chirality is most easily achieved by using the same stereoisomeric configuration in all of the subunits.

For the cyclic backbone moieties, the most favorable binding occurs in nucleoside analogs having 15 the natural D-stereoisomeric configuration shown in Figure 3. Subunits of this type are also readily synthesized, as will be discussed below, using natural D-nucleoside starting material. With reference to Figure 4, it is seen that only structures I and L have 20 chiral linkages between the backbone and recognition moieties. These subunits are readily synthesized in homochiral form by using homochiral starting material, as will be described. For all of the other acyclic structures shown in Figure 4, the one-atom linkages are 25 attached to backbone nitrogen atoms, and are therefore achiral. Also, of course, the methylene spacers are themselves achiral.

II. Protective Group Strategies

Because of the rather high reactivity of the compounds used for activating and/or coupling the 30 subunits, it is generally desirable, and often necessary, to protect the exocyclic ring nitrogens of the recognition moieties. Selection of these protective

groups is primarily determined by the type of intersubunit linkage to be used in the polymer assembled from these subunits, and secondarily determined by the relative reactivity of the nitrogen to be protected.

5 Base-protected nucleosides are also useful starting reagents in a number of the subunit synthesis reactions to be described below. Methods for base protecting a number of the more common ribo- and deoxynucleosides from Example 1 are illustrated in
10 Example 2. The methods detailed in the example are generally applicable for forming nucleosides with amine-protective groups.

When the intersubunit linkage to be used is relatively stable to nucleophiles, and particularly to
15 ammonium hydroxide, then the standard base-protective groups used for nucleic acid chemistry are suitable. Such nucleophile-insensitive intersubunit linkages include carbamate, amide, and sulfonamide linkages. The corresponding nucleophile-sensitive protective groups
20 for the recognition moieties include: benzoyl for the N4 of C; benzoyl or p-nitrobenzoyl for the N6 of A; acetyl or isobutyryl for the N2 of G; and N2,N6-bisisobutyryl for 2,6-diaminopurine residues. Removal of these groups after completion of polymer assembly is effected by
25 treatment with ammonium hydroxide.

In contrast, when the intersubunit linkage to be used is sensitive to nucleophiles, such as ammonium hydroxide, suitable protective groups are those which can be removed by strong non-nucleophilic bases -- via a
30 β elimination mechanism. Such nucleophile-sensitive intersubunit linkages include: carbonate; ester; and, to a lesser extent, triocarbamate linkages. Suitable protective groups for the recognition moieties removable via β elimination include: 2-(4-nitrophenyl)ethoxy

carbonyl or 2-(phenyl sulfonyl)ethoxycarbonyl for both the N4 of C and the N6 of A; and the 9-fluorenylmethoxycarbonyl for the N2 of G and the N2 and N6 of 2,6-diaminopurine residues. Removal of these groups after completion of polymer assembly is effected by treatment with the strong nonnucleophilic base 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU), under stringently anhydrous conditions.

In regard to temporary protection of a nucleophile of the backbone moiety (generally N1 in the above structures), in the general polymer assembly strategy employs selected backbone-protective groups which are readily cleared by mild acid. One primary criterion for selection of protective groups is that they be adequately stable, but not so stable that conditions required for their removal would damage the growing polymer. A principal problem in the case of polymers assembled from cyclic backbone moieties is the particular acid sensitivity of the glycosidic bond linking protected purine residues to the C1 of their backbone moieties. A secondary criterion for selection of the backbone protective group is that it be easily introduced. Based on the above, the following backbone-protecting groups are preferred: for primary hydroxyls, the di(p-methoxy)trityl group; for primary amines, p-methoxytrityl; and for a secondary amine (as in morphilino-type backbone moieties), the phenylisopropoxycarbonyl group. These protective groups can be readily removed by treatment with 0.2 M dichloroacetic acid in dichloromethane.

-18-

III. Subunit Synthesis

A. Cyclic Backbone Moieties

Subunits having a deoxydeoxynucleoside subunit structure (structure A in Figure 3) can be obtained from commercial sources or prepared via literature methods, as described in Example I. The subunits include the following ribosides and deoxyribosides, which are identified according to the structure numbers of the recognition moieties given in Figure 1: adenosine and deoxyadenosine (structure 1); 2,6-diaminopurine riboside and deoxyriboside (structure 2); cytidine and deoxycytidine (structure 3); 4-methoxy-2-pyrimidinone deoxyriboside (structure 4); 2-hydroxy-5-methyl pyrimidine deoxiriboside (structure 5); 2-hydroxypyrimidine riboside (structure 6); guanosine and deoxyguanosine (structure 7); inosine and deoxyinosine (structure 8); thioguanosine and deoxythioguanosine (structure 9); uridine and deoxyuridine (structure 10); thymidine and 5-methyluridine (structure 11); and 5-halouridines and 5-halodeoxyuridines (structure 12).

The 5'-amino-2',5'-dideoxyribonucleosides (structure B in Figure 3) are prepared according to methods detailed in Example 3. Briefly, the selected deoxyribonucleosides, base-protected if necessary, are reacted with triphenyl phosphine, carbon tetrabromide, and lithium azide to form the corresponding 5'-azidonucleoside, which is then reduced by hydrogenation in the presence of a palladium on carbon catalyst. The nucleosides may be obtained as in Example 1, and base-protected as in Example 2. The stereochemistry of the reactant nucleosides is preserved in forming the 5' amino nucleoside analogs.

An alternative reduction method is used in reducing the azide group of 5'-azido-5-bromo uridine, as described in Example 3.2. Here non-catalytic hydrogenation is needed to prevent removal of the ring 5 bromine atom. In forming the 5'-amine guanosine compound, the azide is placed on the 5' position by first tosylating the 5' hydroxyl group, then displacing with azide, as detailed in Example 3.2.

The 3'-amino-2',3'-dideoxyribosnucleosides 10 (structure C in Figure 3) are prepared according to methods detailed in Example 4. Briefly, thymidine which is protected at its 5' hydroxyl is tosylated at its 3' hydroxyl, and this is followed by an intramolecular displacement involving the 2 oxy base substituent. The 15 resulting ring is now opened by treatment with azide, yielding a 3' azido analog of the correct stereoisomeric form. This analog can be converted to a selected-base analog by reacting the azide compound with a selected purine or pyrimidine base. The latter 20 may be base protected, if necessary, for subsequent subunit coupling reactions, as described below. The thymidine or other azide analog is then reduced to produce the desired 3' amine nucleoside. The 25 stereochemistry is of the thymidine starting material is preserved in the synthesis.

Synthesis of the morpholino-type subunit derivatives represented by structure D in Figure 3 are detailed in Example 5 for a variety of different recognition moieties. Briefly, a selected nucleoside, 30 base-protected if necessary, is dissolved in an ammonium salt, such as ammonium baborate, and then reacted with sodium periodate to form transient 2', 3' dialdehydes, which then close upon an ammonium ion to form morpholino ring having 2' and 4' hydroxyls. The compound is then

-20-

treated with sodium cyanoborohydride to remove the ring hydroxyls. The ring nitrogen is preferably protected as a 2-phenylisopropylcarbamate for subsequent subunit coupling. The stereochemistry of the nucleoside starting material is retained.

Deoxyribose subunit structures having a 5' acetic acid group (structure F in Figure 3) can be prepared according the general synthetic scheme described in Example 6, which details the synthesis of 10 the 5' acetic acid compounds represented by structure F. Here a selected deoxyribonucleoside which is protected at the 3' hydroxyl is converted to the 5' aldehyde, and subsequently treated with a 2-carbon Wittig reagent to give the unsaturated acetic acid 15 derivative. Reduction of the side-chain olefin gives the desired 5' acetic acid compound. The reaction preserves the stereochemistry of the starting nucleoside material.

The analogous 5' formate compound (structure E 20 in Figure 3) is formed by treating the above 5' nucleoside aldehyde with a one-carbon Wittig reagent, and hydroslysing the resulting enol to form the corresponding formaldehyde derivative, which is oxidized to the desired acid. The reaction preserves the 25 stereochemistry of the starting nucleoside material.

8. Subunit Synthesis-Acyclic Backbones

The 5-atom chain amino acid subunit represented by Structure I in Figure 4 is prepared according to the 30 general procedures outlined in Examples 7-9. Briefly, an (S)-5 carboxy pyrrolidone was converted to the corresponding stereochemically pure (S)-5-tosylmethyl-2-pyrrolidone by known methods, and then reacted with a selected purine or pyrimidine, to

-21-

form the corresponding (S)-5-methylpurine or pyrimidine pyrrolidone. The displacement reaction retains the original stereospecificity, so that the subunits which are formed are homoisomeric at the site of attachment of 5 the recognition moiety to the backbone carbon.

The purine used in subunit synthesis is preferably contains an electron-withdrawing group at the 6 position, to reduce the reactivity of the 1 and 3 ring nitrogens, i.e., to minimize pyrrolidone coupling at a 10 ring nitrogen. The pyrrolidone-derivized purine or pyrimidine may then be converted to the amine derivative, and base protected, if necessary, prior to the ring opening step which will be described below.

Example 7.1 and 7.2 detail methods for forming the 15 cytosine pyrrolidone and its base-protected derivative. The adenosine pyrrolidone formed in Examples 7.3-7.5 employs 6-chloropurine as the starting material, and the corresponding pyrrolidone is converted to the adenosine derivative through azide formation as 20 described. The adenosine is base-protected, as in Example 7.6, prior to ring opening. A similar approach is used to generate base protected guanine pyrrolidone, starting from 2-amino-6 chloropurine, as described in Examples 7.7-7.9. Similar methods are used in 25 synthesizing 2,6-diaminopurine pyrrolidone, inosine pyrrolidone, and 2-hydroxypyrimidine pyrrolidone, also as detailed in Example 7.

The pyrrolidone is then treated via a series of reactions which cleave the pyrrolidone ring to form an 30 amino acid with a t-BOC protected amine. Examples 8.1-8.4 describe the synthesis of such t-BOC amino acids having one of a number of selected recognition moieties. In a final step (Example 5), the t-BOC protective group may be removed to form the

corresponding amino acid represented by structure I in Figure 4. The amino acid may be used directly for subunit coupling, according to reactions given below. Alternatively, the t-BOC protected compound may be 5 activated at its acid group for use in subunit coupling reactions.

The strategy for forming the subunit represented by structure J in Figure 4 is outlined in Examples 10.1 and 10.2, for forming the cytidine and 10 uridine analog subunits, respectively. Briefly, in forming a pyrimidine type subunit, a 6-member heterocycle, such as a pyrimidine or nicotinate, is modified to contain a reactive methylene on the carbon ring position at which attachment to the backbone is 15 desired. As detailed in Example 10.1, the cytosine analog is formed by reacting 5-amino-5-bromopyrimidine to form the corresponding 5-position carboxaldehyde. In Example 12, the uridine analog is formed by converting 6-hydroxynicotinic esters to the corresponding benzylic 20 alcohols. This compound is converted to the aldehyde by reaction in the presence of manganese dioxide.

The aldehyde compound is then reacted with the desired amino acids, such as 4-aminobutyric acid, with reaction at the amine group producing an unstable imine 25 which is reduced to form the stable amine subunit. The secondary amine can be protected, for subunit coupling involving activation of the acid group, by a tBOC group as described in Example 10.1. The base attachment to the backbone at a backbone nitrogen, through a methylene 30 spacer, insures that the subunits lack chiral centers and so cannot be stereoregular.

To form the subunit structures shown at K in Figure 4, the C-carbon backbone analog of the above compound is prepared, using 3-aminopropionic acid, and


-23-

this compound is further treated with nitrous oxide to form the corresponding N-nitroso compound, which is subsequently reduced with H₂/Pd in the presence of iron salts to give the hydrazino acid subunit.

5

III. Backbone Coupling Reactions

The coupling reactions used in forming the polymer molecules of the invention are stepwise reactions which join one selected subunit or subunit sequence to another selected subunit or subunit sequence. For purposes of the present discussion, the coupling reactions will be described generally with respect to coupling a single subunit B-R₁, having a selected recognition moiety R₁, to another single subunit B-R₂, having the same or a different selected recognition moiety R₂, to form a dimer of the form



where R₁ and R₂ have the specific sequence shown.

A. Subunit Coupling: N₁—N₂ Backbone Configurations


General methods for coupling subunits having an N₁—N₂ backbone configuration are illustrated in Figures 5A and 5B. As will be recalled from Section I above, N₁ and N₂ are nucleophilic backbone groups, such as hydroxyl and amine groups, which can be activated with an electrophile E, to form an activated N₁-E or N₂-E backbone group which can then react with a second N₁—N₂ type backbone moiety to form an N₁—N₂-E-N₁—N₂ backbone-linked dimer. The subunit backbones of this types which have been

-24-

described specifically above are the cyclic backbone structures A-D in Figure 3. In structures A and B, the activated N_2 nucleophile is the 3' hydroxyl group in structure C is the 5' hydroxyl and in structure D, the 5 6' position hydroxyl corresponding to the 5' position hydroxyl in structure C.

In a preferred coupling method, which is illustrated in Figure 5A, a subunit having a selected recognition moiety R_1 is activated with an 10 electrophile E. The star at the recognition moiety indicates any required base protection. As seen in the figure, the selected subunit is protected at its N_1 nucleophile, to ensure that (a) only the N_2 nucleophile is activated and (b) the activated subunit 15 cannot self-polymerize. In structures A, C, and D in Figure 3, in which the backbone protection group is on the 5' hydroxyl, the protective group is preferably an acid-labile group, such as dimethoxytrityl (DMTO).

The activating reagent shown in Figure 5A has 20 the general form:



X is oxygen or sulfur, and C is an active electrophile capable of reacting with a nucleophile, such as a 25 hydroxyl oxygen or amine nitrogen, with displacement of Y, to form the activated subunit:

Activating agents, such as bis-p-nitrophenyl carbonate, which give the carbonyl activated subunit (X=O), are used in forming carbonate and carbamate 30 subunit linkages. Similarly, activating agent, such as thiocarbonyl-di-(1,2,4-triazole) (X=S) are used in forming thiocarbamate linkages.

Subunit activation reactions involving carbonyl activated subunits are detailed in Example 11 for the

-25-

5' -protected, 2' deoxynucleosides represented at A in Figure 4; in Example 12 for the 5'-protected amino nucleosides represented at B in Figure 4; and in Example 13 for the N-protected morpholino-type subunits shown at 5 D in Figure 4. The general reaction conditions used to activate the hydroxyl groups in these structures are generally applicable; subunit activation reactions involving thiocarbonyl-activated subunits are detailed in Example 14 for the 5'-amino nucleosides represented 10 at B; and in Example 15, for the morpholino-type subunits shown at D in Figure 3.

Following the activation reaction, the activated complex is purified by conventional methods, such as silica gel chromatoatography, and then reacted 15 with a second subunit whose selected recognition moiety R₂ will form the next in-sequence recognition moiety in the completed polymer. The coupling reaction is preferably carried out under mild conditions in which the activated group can react with backbone N₂ amine 20 groups, but not N₁ hydroxyl groups. Therefore, the method is suitable for coupling subunits of the type represented by structures B-D in Figure 4, but not subunit structure A. An advantage of this coupling method is that the second subunit -- which contains an 25 amine N₁ nucleophile and a hydroxyl N₂ nucleophile -- will be coupled to the first activated subunit only through the N₁ amine, so it is not necessary to protect the N₂ backbone group. The resulting dimer 30 subunits are therefore coupled through an N₂-E-N₁ bond, as indicated in the figure.

The oligomer can be extended by repeating the above steps of (a) activating the free N₂ nucleophile in the second subunit, separating the activated species from the activating agent, and coupling the activated

-26-

compound with the next-in-sequence subunit, whose backbone is unprotected. This method is used particularly in forming short oligomer blocks by solution methods which will be described below and which 5 are suitable for solid-phase block assembly.

For forming a polymer by solid-phase sequential subunit addition, the second coupling method outlined in Figure 5B is much preferred. The second method differs from the first method in that polymer growth occurs by 10 addition of an excess of activated subunit to an existing subunit or polymer chain, rather than, as in the first method, by addition of an unactivated subunit to an activated chain. In Figure 5B, the existing subunit or subunit chain is shown by a subunit whose 15 recognition moiety is R_1 (second line in Figure 5B). This subunit has a free N_1 backbone nucleophile and an N_2 nucleophile which is protected by a preferably acid-stable linkage to a solid support or by virtue of being linked to a chain of subunits which are linked to 20 a solid support. Methods of forming cyclic backbone subunits which are N_2 protected in this manner are described generally in Examples 12-15. The first subunit (the most recently added subunit in a growing polymer) is now reacted with an activated subunit which 25 thereby becomes the next-in-sequence subunit in the polymer. This activated subunit, which is activated at its N_2 backbone site, and protected at its N_1 site, preferably by an acid-labile protective group, is prepared by methods described above with reference to 30 Figure 6.

As seen in Figure 5B, the coupling reaction adds the N_2 -activated second subunit to the N_1 -protected first subunit to couple the two through an N_2-E-N_1 bond, and form a compound which is

-27-

protected at both free backbone nucleophile sites. This compound is now treated, for example by reaction with acid, to deprotect the acid-labile N₁ protective group on last-added subunit, and the procedure is repeated to 5 build up a desired sequence polymer.

It can be appreciated from the above that the N₂-activated subunit which will form the last-in-sequence subunit must be protected at its N₁ backbone site, to allow selective activation at the N₂ 10 site and to prevent self-polymerization of the activated compound. Also the N₁-deprotected subunit which is to couple to the activated subunit should be protected at its N₂ site to allow selective reaction of its N₁ moiety with the N₂-activated subunit. 15 Therefore, since the reacting subunits are both protected at one backbone site, the method is suitable for coupling nucleosides (structure A in Figure 4) as well as subunits whose cyclic backbones contain both amine and hydroxyl backbone nucleophiles, such as structures B-D 20 in this figure. The reaction methods used in coupling structure A subunits through a carbonate bond are detailed in Example 12. Briefly, a subunit containing a 5' protected backbone moiety is activated at its 3' hydroxyl, and reacted with another subunit (or growing 25 chain) which is protected at its 3' hydroxyl. The coupling reaction is carried out in the presence of a catalyst, such as N-methylimidazole or N,N-dimethylaminopyridine, which is necessary for forming the carbonate bond. For coupling subunits 30 containing structure B-D cyclic backbones, where intersubunit carbamate or thiocarbamate bonds are formed, much milder uncatalyzed coupling conditions, such as those described with reference to the first method above, are suitable.

-28-

The advantage of this second coupling method, for forming a polymer by solid-phase subunit addition, is that a substantial molar excess of the activated subunit can be added to the growing support-bound polymer at each polymer-addition step, to achieve subunit coupling to a very high percentage of the support-bound polymers. This insures that a large percentage of the support-bound polymers will contain the complete sequence of subunits desired. By contrast 10 in the first method, where the growing polymer is activated at its last-added subunit, the efficiency of subunit addition is limited by the efficiency of the activations steps.

Figure 6 shows the dimeric structures produced 15 by coupling the cyclic backbone subunits indicated at A-A through D-D in Figure 4. The nucleoside subunits in structure A in the figure are joined by a carbonate ($Y=O$). In the remaining three structures B-D, the subunits are joined by carbamate ($Y=O$) or thiocarbamate 20 ($Y=S$) bonds. As seen from the figure, all of the subunit linkages are uncharged and achiral, i.e., do not contain chiral centers. In addition, the linkages are stable in aqueous medium, as judged by the ability of polymers to resist hydrolysis over an extended period in 25 neutral aqueous solution.

According to another important feature of the invention, the structures, when joined to form polymers show acceptable Watson/Crick base pairing with complementary polynucleotides.

30 Finally, according to another important feature of the invention, polymers formed from the subunits are stereoregular. This is achieved in the structures shown by (a) using natural nucleosides or nucleoside derivatives or synthetic nucleosides having the natural

-29-

stereoisomeric configuration as subunits, and (b) joining the subunits by achiral intersubunit linkages. Exemplary coupling methods are detailed in Examples 11-15.

5

8. Subunit Coupling: N₁-----E Backbone Configurations

General methods for coupling subunits having an N₁-----E backbone configuration are illustrated in Figures 7A, 7B, and 7C. As will be recalled from 10 Section I above, N₁ is a nucleophilic backbone group, such as a hydroxyl or amine group, and E is an electrophile, such as a carboxyl or sulfonyl group, which, when activated, can react with a second N₁-----E type backbone to form an N₁-----E-N₁ 15 -----E backbone-linked dimer. The subunit backbones of this types which have been described specifically above are the cyclic backbone structures E-H in Figure 3, and the acyclic backbone structures I-N in Figure 4. In the cyclic structures E and F, the N₁ nucleophile is the 20 3' hydroxyl group, and in structures G and H, the amine attached to the 3' nitrogen on the morpholino ring. The E group in all of the cyclic structures is the carboxyl or corresponding sulfonyl group attached to the 5' position of the ribose ring, or to the 6' position of 25 the morpholino ring. In all of the structures shown in Figure 4, the N₁ and E groups are respectively, the backbone amine or hydrazine and carboxylic or sulfonic acid groups on the backbone moiety ends

The first coupling method, which is illustrated 30 in Figure 7A, is analogous to the method described above with reference to Figure 5A, where a first N₁-protected subunit is activated, then coupled directly to a backbone-unprotected subunit which forms the next-in-sequence subunit in the growing polymer.

-30-

The P_1 protective group on the subunit N_1 is preferably an acid-labile protective group, such as t-butoxycarbonyl or a cleavable linker bound to a solid support. Methods for N_1 -protecting cyclic backbone structures are analogous to procedures described above for cyclic structures A-D. Similar methods are effective to protect the amine nitrogens in the acyclic backbone structures. Alternatively, if the polymer is to be constructed on a solid phase support, as described below, the backbone N_1 site may be protected by its attachment to a solid support, with subunit addition to the growing polymer occurring via the activated E electrophile of the last-added subunit.

The activation reaction is designed to yield an activated or chain-terminal moiety of the form $N_1-----E-X$, where X is as described above with reference to Figure 6, and the activated subunit has much the same reactivity toward backbone nucleophilic groups as does the activated subunit in the previously described method. That is, the activation is designed to produce much the same active coupling group as in the $N_1-----N_2$ type backbones, but where the reactive carbonyl or sulfonyl group is provided by the backbone itself rather than by a carbonyl or sulfonyl activating reagent, as in the methods shown in Figure 6.

The activation can be performed readily by reacting the $N_1-----E$ type subunit with a carbodiimide in the presence of p-nitrophenol, where the backbone electrophile is a carbonyl group, or by reacting with a carbodiimide in the presence of imidazole, 1,2,4 triazole or tetrazole, where the backbone is a sulfonyl. Subunit activation reactions involving carbonyl electrophilic groups are detailed in Examples 16 and 17. The general reaction conditions used to

- 31 -

activate the N-amino-morphilino and linear chain backbone carbonyl groups are generally applicable to the other N_1 ----E type backbone structures shown in Figures 3 and 4.

- 5 Following the activation reaction, the activated complex is purified by conventional methods, such as silica chromatography, or, in the case of a support-bound activated chain, simply washed, and then reacted with a second subunit whose selected recognition
10 moiety R_2 will form the next in-sequence recognition moiety in the completed polymer. The coupling reaction yields a dimer whose subunits are therefore coupled through an E- N_1 bond, as indicated in the figure. As above, both subunits must be suitably base protected
15 during the activation and coupling reactions.

The polymer can be extended by repeating the above steps of (a) activating the free E electrophile in the second subunit, (b) separating the activated species from the activating agent, and (c) coupling the
20 activated compound with the next-in-sequence subunit, whose backbone is unprotected.

The second coupling method, which is illustrated in Figure 7B, is directly analogous to the method described above with respect to Figure 5B. Here
25 a first subunit having an E-protected backbone is reacted with a second subunit with an activated E group and a protected N_1 nucleophile, to form a dimer linked through an E- N_1 bond and protected at both free backbone end groups. Where the polymer is being formed
30 by solid-phase synthesis, the P_2 protective "group" takes the form of an acid-stable linkage to a solid support. The N_1 -protected subunit is prepared and activated as above. Coupling conditions generally

-32-

Follow those used in the above cyclic subunit coupling reactions.

In the third coupling method, shown at Figure 7C, the n_1 -protected and E-unprotected subunits (or 5 polymer units) are reacted together in the presence of a suitable E-activating agent, such as a carbodiimide, as indicated

Figure 8 shows the dimeric structures produced by coupling the cyclic and acyclic backbone subunits 10 indicated at E-K in Figures 3 and 4, and indicated at E-E through K-K, respectively. The nucleosides subunits in structure F-F in Figure 3 are joined by an ester linkage. In remaining cyclic backbone structure, G-G, the subunits are joined through a hydrazid or sulfonyl 15 hydrazide linkage. All of the acyclic backbone subunits, shown at I-I, J-J and K-K, are linked through amide (E=carbonyl) or sulfonamide (E=sulfonyl) bonds. As in the above-discussed cyclic backbone subunit 20 structures, all of the subunit linkages are uncharged and achiral, and all of the bonds are reasonably stable in aqueous medium, as judged by the known stability of ester, hydrazide and amide linkages in solution.

According to another important feature of the invention, the structures, when joined to form polymers 25 show Watson/Crick base pairing with complementary polynucleotides.

Finally, as with the N_1 ---- N_2 backbone subunits described above, all of the N_1 ----E backbone structures shown are stereoregular. This is due to (a) 30 the homochiral (structures E-H in Figure 3 and I and L in Figure 4) or achiral (structures J, K, M, and N in Figure 4) nature of the recognition moiety attachment to the backbone moiety, and (b) the achiral subunit linkage.

-33-

C. Subunit Coupling: Alternating Charged and Uncharged Achiral Linkages

In some applications, it may be desirable to introduce one or more charged achiral subunit linkages in the polymer molecules. The backbone charge may be used to enhance polymer solubility in many solution applications or to adjust polymer-target binding constants, as will be described further below. Polymers having regularly spaced charged achiral backbone linkages, e.g., between every second or third subunit, are suitable for the novel diagnostic system which is described below. For purposes of the present discussion, it is assumed that polymeric units composed of two or more subunits which are internally joined by achiral uncharged linkages are to be linked by a charged achiral linkage. These uncharged units are formed by one of the methods described in Sections A and B above.

The dimer subunits which are to be linked are selected such that the free N₂ group of one dimer can be coupled to the free N₁ group of the other dimer through a suitable charged achiral linkage. The preferred linkage is a phosphodiester linkage which requires that the free N₂ group on one subunit and the free N₁ group on the other subunit both be hydroxyls. As can be seen in Figure 3, this condition is met if dimers formed from either structure A or structure B subunits, which both have a free N₂ hydroxyl, are linked to dimers formed from structure A, C, or D subunits which all have a free N₁ hydroxyl.

In a typical coupling method, dimer A, which is protected at its N₁ position, as indicated, is carried through a series of reactions which lead to a reactive phosphoester coupling species linked to the N₂ hydroxyl through a phosphoester bond, as indicated

-34-

in Figure 9. The preferred coupling method, which is detailed in U.S. patent application for "Polynucleotide Assay Reagent and Method", Serial Number 712,396, filed March 15, 1985, is detailed in Examples 23 and 24 below, 5 with respect to the formation of a tetramer have alternating uncharged, stereospecific methylphosphonate bonds, and charged achiral phosphodiester bonds. Briefly, the illustrated method involves first forming nucleotide dimers linked by methylphosphonate bonds, 10 isolating stereoisomeric forms of the dimers and activating one of the stereoisomeric dimers to form a reactive N₁-protected N₂-(p-chlorophenyl-2-cyanoethyl)-phosphate. The activated dimer is then reacted with the second dimer to form a tetramer which 15 is linked alternately by uncharged, stereoisomeric linkages and charged achiral intersubunit linkages.

The phosphodiester linkage method may be incorporated, either in solution or support-type polymer synthesis method, according to the general procedures 20 outlined in Sections A and B for polymer coupling involving achiral, but uncharged linkage reactions. As indicated, the phosphodiester bonds can be used to couple dimeric or polymeric units which are themselves coupled by uncharged achiral bonds, formed as above, or 25 for coupling dimeric units linked by uncharged, chiral but stereoisoeric linkages, such as the separated stereoisomeric forms of methylphosphonate-linked dimers.

For the diagnostics applications described below, it is generally preferred to introduce as few 30 charged linkages as are necessary for achieving adequate polymer solubility in an aqueous medium. The solubility enhancement is generally achieved with 1-3 charged backbone linkages per polymer of about 20 subunits, and preferably no more than about one charged linkage per

-35-

Four subunits. As defined herein, achiral backbone linkages are considered substantially uncharged if they contain less than about one charge backbone linkage per dimeric unit, and preferably one or fewer backbone linkages per tetrameric unit.

IV. Polymer Targeting Considerations

The design considerations applied in preparing a polynucleotide binding polymer for use in the invention, are governed by the nature of the target analyte and the reaction conditions under which the analyte is to be assayed. As a first consideration, there is selected a non-homopolymeric target base sequence against which the polymer is directed. This target sequence is preferably unique to the analyte being assayed, i.e., is calculated to occur only with some defined small probability (such as 1% or less) in an assay mixture containing a given number of unique-sequence bases. The probability of occurrence of a given n-base target sequence is approximately $1/4^n$ -- that is, a given n-base target sequence would be expected to occur approximately once in a polymer containing 4^n bases. Therefore, the probability P that a given n-base sequence will occur in polynucleotides containing a total of N unique-sequence bases is approximately $P=N/4^n$. To illustrate, the probability P that a 9-base target sequence will be found in a 20 kilobase polynucleotide is about $20 \times 10^3 / 2 \times 10^5$ or 0.08, the probability that a 16-base target sequence will be present is about $20 \times 10^3 / 4.3 \times 10^9$ or 0.0000047. From these calculations, it can be seen that a polymer having 9-16 recognition moieties specific for a defined 9-16 base target sequence should have high

-36-

specificity for the target sequence in an assay mixture containing only viral genomes, whose greatest complexities correspond to about 400K of unique-sequence bases.

Similar types of calculations show that a 12 to 5 16 subunit polymer can provide adequate specificity for a viral or bacterial target sequence in an assay mixture containing viral and bacterial genomic material only (largest genomic sizes about 5,000 kilobases), and that a 16 to 22 subunit polymer can provide adequate 10 specificity for a target sequence in a polynucleotide mixture containing mammalian genomic DNA material (genomic sizes of about 5 billion base pairs of unique-sequence DNA).

The polymer/analyte binding affinity, and 15 particularly the temperature at which the polymer just binds with the target sequence (the melting temperature, or T_m) can be selectively varied according to (a) polymer length, (b) the number of hydrogen bonds that can be formed between the recognition moieties and the 20 corresponding, in-sequence bases of the analyte target sequence, and (c) backbone charge density. From a number of studies on model homopolymer duplexes, it is known that the melting temperature of oligonucleotide duplexes in the 10 to 20 bp range increases roughly 3°C 25 per additional base pair where the complementary bases are capable of forming two hydrogen bonds, and about 6°C per additional base pair where the complementary bases are capable of forming three hydrogen bonds. Therefore, the length of a target sequence, which is initially 30 selected to insure high binding specificity with the polymer, may be extended to achieve a desired melting temperature with the complementary-base polymer, under selected assay conditions. Also, where the recognition moieties used in constructing the polymer are the

-37-

standard nucleic acid bases, as illustrated above, the target sequence may be selected to have a high percentage of guanine plus cytosine bases for achieving a relatively high polymer/analyte melting temperature, 5 or a relatively high percentage of adenine plus thymine bases, for achieving a relatively low melting temperature.

The backbone charge density of the polymer must be substantially less than that of the polynucleotide analyte, to allow preferential binding of polycationic reporter molecules to the analyte, under conditions where reporter binding to the polymer does not occur, as already noted. This requirement is met where the spacing between the adjacent negative charges in the 15 polymer backbone is at least twice as great as the spacing between adjacent charged phosphodiester linkages in the analyte. The charge density of the backbone also has an important effect on the polymer/analyte melting temperature, particularly under low salt conditions, 20 where any charge-charge repulsion between the analyte and polymer backbones can act to lower the temperature at which the two can anneal. In general, therefore, a polymer having a less-charged backbone would be expected to show (1) a higher analyte/polymer melting 25 temperature, and (2) less dependence of the melting temperature on salt concentration. Based on these considerations, an uncharged achiral polymer, such as the several polymers described above with respect to Figures 6 and 8, will allow the analyte/polymer 30 annealing reaction in the diagnostic method to be carried out under a wider range of salt-concentrations than a partially charged polymer, such as a polymer formed from alternating charged achiral phosphodiester

-38-

bonds and uncharged linkages which may be either achiral or chiral, but stereospecifically defined.

V. Polymer Assembly Methods

5

A. Geometric assembly

After selecting a desired polymer length and recognition moiety sequence, according to factors considered in Section IV, the polymer is assembled, 10 using the general subunit coupling procedures detailed above. One method of polymer assembly involves initial preparation of an appropriate set of dimers, linking selected dimers to form tetramers, linking of these to form octamers, and so on. This method is carried out in 15 solution, substantially according to methods described with reference to Figures 5A and 7A above. It should be noted that all couplings need not necessarily be between oligomers of equal size. For example, often it is desirable in the last coupling to link a hexadecamer 20 with a tetramer to give a 20-mer or to link a hexadecamer with an octomer to give a 24-mer.

A particular merit of this assembly method is that each coupling product is roughly twice the mass of the precursors and so purification of the product of 25 each coupling is a simplified matter. Example 18 below details the assembly of an 8-subunit carbamate-linked polymer formed by this method.(b)

B. Stepwise Assembly on a Solid Support

30 One preferred method for polymer synthesis is stepwise assembly on a solid support. Here the first subunit in the polymer is attached through its N₂ backbone group to a solid support. Typically, a solid support, such as glass beads derivatized with cleavable,

-39-

preferably acid-stable, long-chain linkers are employed as the support material, and prepared for attachment of N₂ nucleophile, such as a 5' hydroxyl of a nucleoside, as described in Example 19. The glass beads are reacted with a subunit which has a preferably acid-labile N₁ protected group, and an activated N₂ or E backbone group, as detailed in Section III above. The coupling of various types of subunits to a glass-bead support is described generally in Examples 20-22.

After coupling the second subunit (or polymer unit which may be assembled in solution) to the support, any unreacted linker nucleophiles are capped by addition of a suitable capping reagent, such as p-nitrophenyl acetate, and thereafter the support is washed and filtered. The protecting group on the N₁ terminal subunit is removed, typically by acid treatment, and after neutralization, the support is then reacted with an excess of the next-in-sequence subunit (or polymer unit) which is activated at its free N₂ backbone moiety. The excess of activated subunit maximizes the number of support-bound subunits which are chain-elongated. That is, one feature of the solid support assembly method is the need for high coupling efficiencies at each subunit addition step, and the concentration of added activated subunit is selected to maximize this efficiency. Chain elongation is continued in this manner, with capping of failure sequence, after each subunit addition, until the polymer of the desired length and sequence is achieved. The general method is illustrated in Example 20 for the preparation of a 14-subunit carbonate-linked polymer, in Example 21, for the synthesis of a 19-subunit carbamate-linked polymer, and in Example 22, for the assembly of a 19-subunit amide-linked polymer.

-40-

After addition of the last-in-sequence subunit, the polymer may be capped with a suitable charged or uncharged group coupled to the terminal N₁ group. If the backbone assembly has been carried out exclusively with uncharged achiral linkages, the capping reagent is preferably a charged group which imparts an end terminal charge to the polymer. After capping the polymer, the polymer is cleaved from the support, e.g., by treatment with a nucleophile, such as ammonium hydroxide, and the polymer is purified, such as by anion exchange chromatography. The assembled, purified polymers are attached to a solid support, by methods to be considered below.

The polymer design principles discussed above are illustrated in Examples 18 for a solution synthesis from preassembled dimeric units, in Examples 20-23 for the preparation of a variety of uncharged achiral linkages, and in Example 24, for the preparation of an alternating charge type polymer.

20

VI. Diagnostic Reagent

A. Solid Support Reagent

The reagent of the invention is formed by coupling multiple binding polymers from above to a solid support. Alternatively, the polymers may be synthesized in a stepwise or block fashion, on the support, as described above for the carbamate-linked polymers. The polymers may be coupled directly to (or formed directly on) the support, e.g., through an OH end group on the polymer to an OH-reactive group on a solid support, such as activated agarose, cellulose, or the like. However, direct coupling often places the support-proximal subunits too close to the support to allow base-

-41-

complementary binding between the analyte and the proximal subunit recognition moieties. Therefore, the polymer molecules preferably are each linked to the solid support through a spacer arm adapted to distance 5 the polymer from the surface region of the support so as to allow substantially unhindered binding between the polymer and analyte target sequence.

The spacer arm is preferably an unbranched chain having a total chain length of at least 6 atoms, 10 and has suitable reactive end groups for attachment to the support, at one end, and to the polymer at the other end. A variety of types of spacer arms, particularly carbon-containing chains of various lengths and hydrophilicity, are well known, as are reactive groups 15 used in spacer-arm coupling reactions. Example 25 below describe the synthesis of an aminohexyl spacer arm, its attachment to the 5' end of mixed methylphosphonate/phosphodiester polymer, and coupling to a solid support. Example 26 below details the 20 preparation of a polymer support having multiple surface-bound, linear-chain spacer arms, for use in forming a diagnostic reagent having carbamate-linked polymers. The method of Example 26 is illustrated in Figure 10. The support shown in the figure is an 25 aminomethylated polystyrene which is first reacted with succinic anhydride to form a carboxylated derivative. Activation of the support with di(succinimido)carbonate and reaction with 6-aminohexanol leads to the 13-atom terminal-hydroxyl spacer arm shown.

-42-

Preferred solid supports include agarose, cellulose, nitrocellulose, latex, polystyrene, and other commercially available strip or particle-bead support material having surface-reactive or activatable groups 5 which allow efficient coupling of polymer molecules, particularly through polymer-bound spacer arms. The concentration of polymers coupled to the support surface is preferably selected so as to allow a 10-1000 fold molar excess of polymer molecules to analyte molecules 10 when a suitable sample volume of assay material is mixed with the support, in the diagnostic procedure, as will be described below. A procedure for coupling a target binding polymer to agarose beads through the aminohexyl spacer arm from Example 25 is described in the same 15 example.

8. Reporter

The reporter of the diagnostic system of the invention is composed of two parts: (1) a polycationic 20 moiety or tail designed to bind electrostatically to a fully charged polynucleotide, under conditions where the reporter does not bind to the less charged binding polymer carried on the diagnostic reagent, and (2) one or more reporter groups attached to the tail adapted to 25 produce a signal by which the presence of the reporter can be detected. Polycationic, as the term is used herein, encompasses tails having two or more suitably spaced cationic groups.

The cationic tail is preferably constructed to 30 provide at least two positively charged groups which are spaced for binding to adjacent negative charges on the sugar-phosphate backbone of the polynucleotide analyte. At the same time, the spacing between adjacent charges on the cationic tail is such that electrostatic binding

-43-

to the reagent polymer backbone which involves more than half of the reporter charges is energetically unfavorable. For example, in the above-described polymer having alternating uncharged phosphonate and charged phosphate linkages, the distance between adjacent negative charges in the polymer backbone is approximately twice that in a polynucleotide backbone. Therefore, binding between substantially all of the charged groups of the cationic tail and the alternately spaced negative charges of the polymer backbone would require energetically unfavorable contortion of the polymer backbone. It can be appreciated that where the polymer backbone has an alternating charged/uncharged configuration, the spacing between adjacent positive charges in the cationic tail should be close to the minimum spacing which provides strong electrostatic binding between the reporter tail and the polynucleotide backbone. The charge-spacing requirement in the reporter becomes much less critical, of course, where the reagent polymer has a density of negative charge less than one per two subunit linkages or where the reagent polymer has an uncharged backbone.

It is also noted that when the polymer backbone has an alternating charged/uncharged configuration, such as charged phosphodiester linkages alternating with uncharged methylphosphonate linkages, the cationic reporter can most effectively discriminate between the fully charged polynucleotides and the polymer when its cationic moieties are unable to hydrogen bond to the uncharged linkage, such as to the double-bonded oxygen of the methylphosphonate linkage. For this reason, it is generally advantageous to use quaternary ammonium ions for the cationic groups in such a reporter.

-44-

The number of cationic moieties in the reporter tail may vary from two up to about 8 or more, according to the total electrostatic attraction required to bind the reporter to the polynucleotide analyte under binding conditions where the reporter does not bind to the reagent polymer backbone. For reporters having relatively large reporter groups, such as enzymes, multiple electrostatic binds may be required to attach the reporter tail to the analyte backbone. A reporter tail having a number of spaced cationic moieties is particularly suitable for use with a reagent whose polymer backbone is uncharged and thus cannot form electrostatic bonds to the tail. Methods for constructing a cationic tail suitable for use in the invention are outlined in Figures 11-13. With reference first to Figure 11, an N-methyl amino acid is N-protected with di-t-butyl dicarbonate (BOC), activated with carbonyl diimidazole, then coupled through an amide linkage to dimethylamine. After deprotection, the amide is reacted with an N-protected, carbonyl diimidazole-activated amino acid from above, to form a diamide compound which is shown at the center in Figure 11. The deprotection reaction and reaction with N-protected diimidazole-activated amino acid, are repreated until the desired-length polyamide is formed. Details of the synthetic reactions are set forth in Examples 28-30.

A reporter group is most readily attached, typically, to a primary amine group in the polycation. To attach a primary amine to the secondary-amine end of the Figure 11 compound, according to one suitable method, an amino acid, e.g., 4-amino butyric acid, is BOC-protected, activated with diimidazole, and reacted with the deprotected polyamine, as illustrated in Figure 12. The resulting BOC-protected compound can then be

-45-

reduced, after treatment with trifluoroacetic acid to remove the BOC group, by reaction with borane-tetrahydrofuran. These procedures are described in Examples 31-32.

5 Figure 13 shows a reaction scheme for converting polyamine, such as synthesized above, to a polyquaternary ammonium salt. The procedure involves protection of the terminal 1° amine followed by reaction with methyl iodide, to form the poly quaternary ammonium
10 salt, and deprotection with trifluoroacetic acid.
Example 33 below gives details of the method.

15

20

25

30

-46-

Preferred solid supports include agarose, cellulose, nitrocellulose, latex, polystyrene, and other commercially available strip or particle-bead support material having surface-reactive or activatable groups which allow efficient coupling of polymer molecules, particularly through polymer-bound spacer arms. The concentration of polymers coupled to the support surface is preferably selected so as to allow a 10-1000 fold molar excess of polymer molecules to analyte molecules when a suitable sample volume of assay material is mixed with the support, in the diagnostic procedure, as will be described below. A procedure for coupling a target binding polymer to agarose beads through the aminohexyl spacer arm from Example 25 is described in the same example.

B. Reporter

The reporter of the diagnostic system of the invention is composed of two parts: (1) a polycationic moiety or tail designed to bind electrostatically to a fully charged polynucleotide, under conditions where the reporter does not bind to the less charged binding polymer carried on the diagnostic reagent, and (2) one or more reporter groups attached to the tail adapted to produce a signal by which the presence of the reporter can be detected. Polycationic, as the term is used herein, encompasses tails having two or more suitably spaced cationic groups.

The cationic tail is preferably constructed to provide at least two positively charged groups which are spaced for binding to adjacent negative charges on the sugar-phosphate backbone of the polynucleotide analyte. At the same time, the spacing between adjacent charges on the cationic tail is such that electrostatic binding

-47-

to the reagent polymer backbone which involves more than half of the reporter charges is energetically unfavorable. For example, in the above-described polymer having alternating uncharged phosphonate and charged phosphate linkages, the distance between adjacent negative charges in the polymer backbone is approximately twice that in a polynucleotide backbone. Therefore, binding between substantially all of the charged groups of the cationic tail and the alternately spaced negative charges of the polymer backbone would require energetically unfavorable contortion of the polymer backbone. It can be appreciated that where the polymer backbone has an alternating charged/uncharged configuration, the spacing between adjacent positive charges in the cationic tail should be close to the minimum spacing which provides strong electrostatic binding between the reporter tail and the polynucleotide backbone. The charge-spacing requirement in the reporter becomes much less critical, of course, where the reagent polymer has a density of negative charge less than one per two subunit linkages or where the reagent polymer has an uncharged backbone.

It is also noted that when the polymer backbone has an alternating charged/uncharged configuration, such as charged phosphodiester linkages alternating with uncharged methylphosphonate linkages, the cationic reporter can most effectively discriminate between the fully charged polynucleotides and the polymer when its cationic moieties are unable to hydrogen bond to the uncharged linkage, such as to the double-bonded oxygen of the methylphosphonate linkage. For this reason, it is generally advantageous to use quaternary ammonium ions for the cationic groups in such a reporter.

- 48 -

The number of cationic moieties in the reporter tail may vary from two up to about 8 or more, according to the total electrostatic attraction required to bind the reporter to the polynucleotide analyte under binding conditions where the reporter does not bind to the reagent polymer backbone. For reporters having relatively large reporter groups, such as enzymes, multiple electrostatic binds may be required to attach the reporter tail to the analyte backbone. A reporter tail having a number of spaced cationic moieties is particularly suitable for use with a reagent whose polymer backbone is uncharged and thus cannot form electrostatic bonds to the tail. Methods for constructing a cationic tail suitable for use in the invention are outlined in Figures 11-13. With reference first to Figure 11, an N-methyl amino acid is N-protected with di-t-butyl dicarbonate (BOC), activated with carbonyl diimidazole, then coupled through an amide linkage to dimethylamine. After deprotection, the amide is reacted with an N-protected, carbonyl diimidazole-activated amino acid from above, to form a diamide compound which is shown at the center in Figure 11. The deprotection reaction and reaction with N-protected diimidazole-activated amino acid, are repreated until the desired-length polyamide is formed. Details of the synthetic reactions are set forth in Examples 28-30.

A reporter group is most readily attached, typically, to a primary amine group in the polycation. To attach a primary amine to the secondary-amine end of the Figure 11 compound, according to one suitable method, an amino acid, e.g., 4-amino butyric acid, is BOC-protected, activated with diimidazole, and reacted with the deprotected polyamine, as illustrated in Figure 12. The resulting BOC-protected compound can then be

-49-

reduced, after treatment with trifluoroacetic acid to remove the BOC group, by reaction with borane-tetrahydrofuran. These procedures are described in Examples 31-32.

5 Figure 13 shows a reaction scheme for converting polyamine, such as synthesized above, to a polyquaternary ammonium salt. The procedure involves protection of the terminal 1° amine followed by reaction with methyl iodide, to form the poly quaternary ammonium 10 salt, and deprotection with trifluoroacetic acid. Example 33 below gives details of the method.

15

20

25

30

-50-

The one or more reporter groups in the reporter should be (1) readily attached to the cationic tail, and (2) capable of generating an easily detected signal. either when the reporter is bound to a polynucleotide
5 backbone, or after the reporter has been eluted from the analyte. Small reporter groups that include chromophores, such as nitroaniline or other strongly absorbing dyes, and fluorophores, such as dansyl or rhodamine-based fluorescent molecules, are suitable and have the
10 advantage that they can be readily detected by photometric equipment, or in the case of dyes, by visual inspection. Radioisotopic reporter groups may provide advantages in diagnostic sensitivity, but reporter detection may be more complex and expensive. Stable
15 paramagnetic molecules, such as nitroxide spin labels, may also be used, the binding of the reporter to the polynucleotide being detected by broadening of electronic spin resonance (esr) absorption lines characteristic of immobilized paramagnetic species.

20 Another class of suitable reporter groups include ligand molecules, and preferably small antigenic molecules capable of binding specifically and with high affinity to anti-ligand molecules. Exemplary ligand/anti-ligand pairs include antigen/antibody, lectin/
25 carbohydrate, and biotin/avidin. The anti-ligand molecule is part of a signal-producing binding conjugate which also includes a signal-producing group, such as a chromophore, fluorophore, or enzyme by which the presence of ligand groups can be detected, when ligand/
30 anti-ligand binding has occurred.

The reporter may have enzyme reporter moieties, particularly, as noted above, where the reporter tail has more than two cationic groups. Representative classes of enzymes are oxidoreductases, typified by

-51-

luciferase; glucose oxidase; galactose oxidase and catalase; hydrolases, typified by various kinds of phosphatases; glycosyl hydrolases, such as β -galactosidase; peptidases; and lyases.

5 Typically the reporter group or groups are coupled to an amine of the polycationic tail, and preferably a primary amine, according to known coupling methods. In one preferred method, illustrated in Figure 15, a polyamine is reacted with a suitable bifunctional 10 coupling agent, such as 4-fluoro-3-nitrophenylazide, and then coupled to a reporter group, such as an enzyme. A variety of bifunctional reagents for coupling amines to reactive reporter groups such as amine, carboxyl, OH, and sulhydryl groups, are well known. A detailed method 15 for forming a tetracationic reporter with an alkaline phosphatase reporter group is given in Example 38. In another preferred procedure, illustrated in Figure 15, a reporter is prepared by reacting bis-3,3'-aminopropyl-methylamine with an amine-reactive dansyl group. The 20 reaction scheme in the figure also indicates how the amino moieties of the reporter tail can be fully alkylated before or following reporter coupling to the tail. Details of the procedure are given in Example 34.

25

30

-52-

VII. Diagnostic Method

This section describes the use of the diagnostic system described above for determination of a polynucleotide analyte. The analyte may be one which normally exists in a single-stranded form, such as messenger RNA (mRNA), ribosomal RNA (rRNA) or a single-stranded RNA or DNA viral genome, or one which exists under physiological conditions in a double-stranded or duplex form, such as double-stranded viral RNA, RNA/DNA viral replicative intermediates, and duplex DNA, such as that derived from a virus, a bacterium, or eukaryotic cell. The considerations and rationale used in selecting a target sequence in the analyte polynucleotide, against which the reagent polymers are targeted, are considered in Section I.

In performing the diagnosis, a sample to be assessed for analyte is collected, typically by conventional clinical sample-handling techniques. Where the analyte is a virus or bacteria-derived polynucleotide, it is often useful to first process the sample to remove larger non-analyte cell material. For example, in assaying for the presence of a viral pathogen, it is often useful to filter the sample through a 0.2 micron pore-sized membrane to remove bacterial material. In assaying for the presence of a bacterial pathogen, it is often useful to filter the sample through a 1.0 micron pore-sized membrane to remove eucaryotic cells, which may also be present in the sample. Typical sample preparation methods are described for diagnosis of viral pathogens in Examples 36 and 37.

To prepare the sample analyte material in a form suitable for binding to the reagent polymer, the sample should be treated to free the organism's nucleic

-53-

acid. For organisms lacking cell walls, detergents and/or chaotropic salts are generally adequate. For organisms having cell walls, alkali (when the analyte is DNA) or suitable enzymes (e.g., lysozyme for many bacteria) can be used. If desired, the freed nucleic acids can be conveniently separated from proteins and other contaminants by addition of a chaotropic salt (sodium trichloroacetate) followed by selective precipitation of the nucleic acid with ethanol.

One efficient method for freeing and isolating nucleic acid material from viral or cell components has been described by the inventor in Anal Biochem (1983) 133:79. The method, which is detailed in Example 36, involves suspending the sample in 4M trichloroacetate, 100 mmol EDTA, to denature and solubilize proteinaceous material, then precipitating freed nucleic acid material in the salt solution by the addition of an equal volume of cold ethanol. A carrier polynucleotide, such as polyuridylic acid, may be added to facilitate nucleic acid precipitation. After a short chilling time, the precipitated nucleic acid is pelleted by centrifugation, and washed with aqueous ethanol to remove salt.

The nucleic acid fraction is resuspended in annealing buffer having a selected salt concentration and a divalent cation chelating agent. An annealing buffer containing about 100 mmol or less of monovalent salt, such as NaCl, and about 10 mmol chelating agent, such as EDTA, is generally suitable for binding of a polynucleotide which exists normally in a duplex DNA form. Salt concentration significantly below 100 mmol may be difficult to achieve with precision. Higher salt concentrations, particularly above about 0.5 M, tend to allow duplex formation between complementary polynucleotide strands, leading to competition between the reagent

polymer and the complementary strand for binding to the analyte polynucleotide. Duplex formation between complementary polynucleotides is also inhibited by the chelating agent, which acts to sequester Mg^{+2} and 5 Ca^{++} ions in the annealing mixture. Where the analyte is an RNA, it may be advantageous to treat the sample with DNase to prevent competition between dissociated DNA and the RNA analyte for binding to the reagent polymer.

10 The annealing reaction is preferably carried out at a temperature which is about 5°C to 15°C below the melting temperature of the analyte/polymer duplex structure which forms during the reaction period. This annealing temperature favors faithful base-sequence 15 pairing between the analyte target sequence and the polymer. As indicated above, where the analyte polynucleotide normally exists with its complementary strand as a duplex structure, the reaction temperature is preferably higher than the melting temperature of the 20 native polynucleotide duplex, to avoid undesired pairing of the analyte with its complementary polynucleotide competing with the desired pairing of the analyte with the reagent polymer. At an annealing buffer concentration of about 100 mmol monovalent cation, annealing 25 temperatures in the range of 24° to 60°C are generally suitable. As noted earlier the actual optimal annealing temperature is a function of the length of the binding polymer, its ratio of A + T to C + G recognition moieties, and, for partially charged polymers, the salt 30 concentration.

Depending on the structural characteristics of the polymer, as discussed above, the melting temperature of the analyte/polymer duplex structure may be substantially higher than a preferred reaction

-55-

temperature, such as 37°C, in the particular annealing buffer employed, such as 100 mmol monovalent salt. In such cases, it may be convenient to lower the melting temperature of the polymer/analyte duplex structure to 5 the desired temperature by the addition of a denaturant such as formamide. To determine the amount of formamide needed to achieve the desired melting temperature, the melting curve of the polymer and the target sequence, which may be a synthetic oligonucleotide having the 10 analyte target sequence, is determined by conventional means, and at a number of different denaturant concentrations, and, in the case of added formamide, typically ranging between about 5% and 50% by volume of denaturant. From this determination, the amount of 15 formamide needed in the annealing buffer in order to achieve a melting temperature about 5° to 15° above the desired reaction temperature is determined.

The analyte sample in the reaction buffer is added to the diagnostic reagent, preferably under 20 conditions where the binding polymers of the reagent are present in a 10-1000 molar excess over the molar concentration of analyte molecules in the assay mixture. The polymer/polynucleotide annealing reaction is carried out at the selected reaction temperature for 25 a period sufficient to allow substantial polymer/analyte annealing, typically between 10 minutes and 3 hours. The solid-support reagent is washed one or more times to remove unbound material.

Reporter is then added to the washed reagent 30 under preselected conditions to bind reporter molecules to the fully charged backbone of the reagent-bound analyte. The spatial/charge characteristics of the reporter, which permit selected binding of the reporter to the polynucleotide backbone have been discussed

-56-

above. One important factor, where the reagent polymer has some negative backbone charges, is the salt concentration of the binding medium. At very low salt concentrations, electrostatic interactions are stronger, 5 and this may lead to undesirable binding of the reporter to the widely spaced anionic groups of the reagent polymer. In contrast, at very high salt concentrations, shielding of electrostatic charges may prevent desired binding of the reporter to the closely spaced anionic 10 groups of the analyte backbone. The optimal salt concentration of the binding medium is the maximum or near-maximum concentration of monovalent salt which permits adequate electrostatic binding of the reporter to the fully charged analyte backbone. This optimal 15 salt concentration can be determined by equilibrium dialysis techniques, in which binding of the diffusible reporter to a nondiffusible polynucleotide is measured as a function of salt concentration of the suspending medium. Optimal ionic-strength conditions for reporter 20 binding to the analyte may also be determined readily by binding the reporter to immobilized polynucleotide, under low salt conditions, and eluting the reporter with a salt gradient.

The binding components in the diagnostic system, as they function in the diagnostic method of the invention, are shown below in Figure 16. Here "S" is the solid support having a number of binding polymers attached to its surface through spacer arms indicated by sawtooth lines, and the "m" and "p" subunit linkages 25 represent uncharged, stereoisomerically defined methylphosphonate and charged phosphodiester linkages, respectively. The reporter has a dicationic tail and an R reporter group. For illustrative purposes, each 30 polymer has the sequence of recognition moieties

-57-

complementary to the selected 16-base target sequence in Herpes simplex virus, Types I and II, as described in Example XXI. The base-complementary binding of one of these polymers to the target sequence in a Herpes simplex analyte polynucleotide is shown.

The reporter shown in the figure is the dicationic reporter from Example 34. Each reporter is adapted to bind through electrostatic attraction to a pair of adjacent phosphodiester bonds in the 10 polynucleotide through electrostatic attraction with adjacent phosphodiester bonds. The reporter molecules are shown in their expected binding configuration, where substantially every phosphodiester linkage is paired with a reporter cation, and the reporter molecules are 15 arrayed head-to-head and tail-to-tail. Assuming a maximum density of bound reporter molecules, it can be appreciated that an N-base analyte can bind up to about $N/2$ reporter molecules. More generally, depending on the size of analyte and the relative number of both, 20 reporter moieties and cationic groups per reporter, the assay method readily leads to binding of thousands to several hundred thousand or more reporter molecules to each reagent-bound analyte molecule. The sensitivity of detection can therefore be between 2 and 4 orders of 25 magnitude greater than in existing types of polynucleotide-based diagnostics, where analyte detection is generally based on one or a few probe molecules per analyte molecule, with each probe typically containing roughly 100 reporter moieties.

30 After reaction with the reporter solution, typically at room temperature for 1-2 minutes, the reagent is washed to remove unbound reporter, and then can be assessed directly for bound reporter. In determining the amount of reporter associated with the

-58-

reagent, it may be desirable, particularly in the case of fluorescent or chromophoric reporter groups, to elute the reporter from the reagent with a high salt solution and then assess the eluate for reporter. Other types of reporter groups, such as enzymes, can be readily assessed with the reporters either bound to or eluted from the reagent. Methods for determination of a variety of different reporter groups, such as those mentioned above, are well known. Examples 36 and 37 illustrate diagnostic procedures based on determination of fluorescent and enzymatic reporters, respectively.

15

20

25

30

-50-

From the foregoing, it can be appreciated how various objects and features of the invention are met. The diagnostic reagent can be readily tailored, by reagent polymer design, for the detection of any ribo-
5 or deoxyribopolynucleotide having a unique base pair sequence. Further, the reagent polymer can be tailored to bind a given target sequence with high sequence specificity at a convenient temperature.

For detection of duplex polynucleotides, the
10 reaction can be carried out under low-salt and/or denaturing conditions which prevent competition from complementary polynucleotide strands for analyte binding to the reagent. This diagnostic system therefore provides the advantage of the prior art solid-support,
15 single-probe polynucleotide diagnostic system, in that competition between complementary strands is eliminated, but avoids the rather laborious step associated with that system in attaching single-strand test nucleic acids to the solid support. At the same time, the
20 system avoids the problems associated with the dual-probe polynucleotide diagnostic system described earlier, in that analyte detection is based on pseudo-first order kinetics, and only one sequence-specific binding polymer is required.

25 According to another important feature of the invention, reporter binding to the analyte is based on sequence-independent electrostatic interactions rather than sequence-specific binding, as in existing types of polynucleotide diagnostics. Accordingly, the reporter
30 itself can be prepared relatively cheaply, can react with the analyte quickly and under a wide range of conditions, and, most importantly, can bind to the analyte at a density ranging up to multiple reporter moieties per polynucleotide subunit in the analyte.

-60-

Accordingly, the sensitivity of the diagnostic system can be in the range of 2 to 4 or more orders of magnitude greater than existing tests, which rely on detection of one or a few probes, containing a limited 5 number of reporter moieties, per analyte molecule.

The following examples illustrate preparation and use of assay systems constructed according to particular embodiments of the invention, but are in no 10 way intended to limit the scope of the invention.

Example 1

Preparation of ribonucleosides and deoxyribonucleosides

15 The following nucleosides are obtained from Sigma Chemical Co., St. Louis, MO: deoxyuridine, deoxyguanosine, thymidine, deoxyadenosine, deoxycytidine, 5-bromodeoxyuridine, deoxyinosine, 2,6-diamino-9-(2-deoxy- β -D-erythro-pentofuranosyl)9H-purin 20 e (2,6-diaminopurine deoxyriboside), uridine, guanosine, 5-methyluridine, adenosine, cytidine, 5-bromouridine, inosine.

2,6-Diamino-9-(β -D-ribofuranosyl)-9H-purine (2,6-diaminopurine riboside) is obtained from Pfaltz and 25 Bauer, Inc., Division of Aceto Chemical Co., Inc., Waterbury, CT.

The following nucleosides are prepared by the literature methods indicated:

30 1-(2-Deoxy- β -D-erythro-pentofuranosyl)-2-pyrimidinone (2-hydroxypyrimidine deoxyriboside) is prepared by the method of P. Kohler, E. Volz, U. Sequin, and C. Tamm in Nucleic Acid Chemistry (L.B. Townsend and R.S. Tipson, eds) John Wiley and Sons, Inc. (1976).

-61-

1-(2-Deoxy- β -D-erythro-pentofuranosyl)-4-methoxy-2-pyrimidinone is prepared by the following procedure:

1-(3',5'-Di-O-benzoyl-2-deoxy- β -D-erythro-pentofuranosyl)-4-methylthio-2-pyrimidinone (prepared as in D.

5 Cech and A. Holy, Collection of Czechoslov Chem Comm (1977) 42:2246) is treated with 200 mL of 0.2M sodium methoxide solution. The resulting solution is allowed to stand overnight at room temperature. This solution is then neutralized with Dowex 50X8 (H+ form) and

10 filtered; the residue is dissolved in water (100 mL) extracted with ether (2.50 mL) and the aqueous phase evaporated. The residue is an amorphous material which is used directly in succeeding reactions.

2-Amino-9-(2-deoxy- β -D-erythro-pentofuranosyl)-1,
15 9-dihydro-6H-purine-6-thione (deoxythioguanosine) is prepared by the procedure of R.H. Iwamoto, E.M. Acton, and L. Goodman, J Med Chem (1963) 6:634.

1-(β -D-Ribofuranosyl)-2-pyrimidinone
(2-hydroxypyrimidine riboside) is prepared by the
20 procedure of U. Niedballa and H. Vorbruggen, J Org Chem (1974) 39:3668.

1-(2-Deoxy- β -D-ribofuranosyl)-4-methoxy-2-pyrimidinone (2-hydroxypyrimidine deoxyriboside) is prepared by the procedure of R. Wightman and D. Holy, Collection of
25 Czechoslov Chem Comm (1973) 38:1381.

2-Amino-9-(β -D-ribofuranosyl)-1,6-dihydro-6H-purine-6-thione (thioguanosine) is prepared by the procedure of J.J. Fox, I. Wempen, A. Hampton and I.L. Doerr, J Amer Chem Soc (1958) 80:1669.

30

Example 2

Preparation of Base-Protected Nucleotides

Dimethoxytrityl chloride, N-benzoyladenosine,
N-benzoyl-2'-deoxyadenosine, N-benzoylcytidine,

-62-

N-benzoyl-2'-deoxycytidine and N-isobutyryl-2'-
deoxyguanosine are obtained from Sigma Chemicals, St.
Louis, Missouri. 9-Fluorenylmethoxycarbonyl chloride
(FMOC chloride), trimethylchlorosilane, isobutyric
5 anhydride, 4-nitrobenzoyl chloride and all organic
solvents for reactions and chromatography are obtained
from Aldrich Chemical Co., Milwaukee, Wisconsin. Silica
Gel is obtained from EM Science, Cherry Hill, New
Jersey.

10

2.1 Guanosine.

The N-2 9-fluorenylmethoxycarbonyl derivative
is prepared by the procedure below which is general for
the protection of nucleoside amino groups:

15 Guanosine (1 mmol) is suspended in pyridine (5
mL) and treated with trimethylchlorosilane (5 mmol).
After the solution is stirred for 15 minutes
9-fluorenylmethoxycarbonyl chloride (5 mmol) is added
and the solution maintained at room temperature for 3
20 hours. The reaction is cooled in an ice bath and water
(1 mL) is added. After stirring for 5 minutes conc.
ammonia (1 mL) is added and the reaction stirred for 15
minutes. The solution is evaporated to near dryness and
the residue dissolved in chloroform (10 mL). This
25 solution is washed with sodium bicarbonate solution (5
mL, 10%), dried over sodium sulfate and evaporated. The
residue is coevaporated several times with toluene and
the product chromatographed on silica gel using a
gradient of methanol in methylene chloride (0-50%).

30 N-Isobutyrylguanosine is prepared by the method
of Letsinger and Miller, J Amer Chem Soc (1969)
91:3356.

-63.

N-2 Acetylguanosine is obtained by the method of C.B. Reese and R.S. Saffhill, J Chem Soc Perkin Trans (1972) 1:2937.

5 2.2 Deoxyguanosine

The N-2 9-fluorenylmethoxycarbonyl derivative is prepared by the method of J. Heikkila and J. Chattpadhyaya, Acta Chem Scand (1983) 837:263.

The N-2 acetyl derivative is obtained from
10 Research Plus Inc., Bayonne, N.J.

2.3 Deoxyadenosine

The N-6 2-(4-nitrophenyl)-ethoxycarbonyl derivative is prepared by the method of F. Hinmelsbach
15 and W. Pfleiderer, Tetrahedron Lett (1983) 24:3583.

N-6 4-Nitrobenzoyl-2'-deoxyadenosine is prepared using the procedure above for FMOC-guanosine except that 4-nitrobenzoyl chloride is substituted for FMOC chloride.

20 The N-6 2-(phenylsulfonyl)-ethoxycarbonyl derivative is prepared by the procedure for FMOC guanosine except the 2-(phenylsulfonyl)-ethyl chloroformate (obtained from N. Balgobin, S. Josephson and B. Chattpadhyaya, Tetrahedron Lett (1981) 22: 3667) is used as the acylating agent and N-methylimidazole or
25 pyridine is used as the solvent.

2.4 Adenosine

30 The N-6 2-(4-nitrophenyl)-ethoxycarbonyl derivative is prepared by the method of F. Hinmelsbach and W. Pfleiderer, Tetrahedron Lett (1983) 24:3583.

N-6 4-Nitrobenzoyladenosine is prepared using the procedure above for FMOC-guanosine except that

-64.

4-nitrobenzoyl chloride is substituted for FMOC chloride.

The N-6 2-(phenylsulfonyl)-ethoxycarbonyl derivative is prepared by the procedure for FMOC guanosine except the 2-(phenylsulfonyl)-ethyl chloroformate (obtained from N. Balgobin, S. Josephson and B. Chattopadhyaya Tetrahedron Lett (1981) 22:3667) is used as the acylating agent and N-methylimidazole or pyridine is used as the solvent.

10

2.5 Deoxycytidine

The N-4 2-(4-nitrophenyl)-ethoxycarbonyl derivative is prepared by the method of F. Himmelsbach and W. Pfleiderer, Tetrahedron Lett (1983) 24:3583.

15

The N-6 2-(phenylsulfonyl)-ethoxycarbonyl derivative is prepared by the procedure for FMOC guanosine except the 2-(phenylsulfonyl)-ethyl chloroformate (obtained from N. Balgobin, S. Josephson and B. Chattopadhyaya Tetrahedron Lett (1981) 22:3667) is used as the acylating agent and N-methylimidazole or pyridine is used as the solvent.

2.6 Cytidine

The N-4 2-(4-nitrophenyl)-ethoxycarbonyl derivative is prepared by the method of F. Himmelsbach and W. Pfleiderer, Tetrahedron Lett (1983) 24:3583.

The N-6 2-(phenylsulfonyl)-ethoxycarbonyl derivative is prepared by the procedure for FMOC guanosine except the 2-(phenylsulfonyl)-ethyl chloroformate (obtained from N. Balgobin, S. Josephson and B. Chattopadhyaya Tetrahedron Lett (1981) 22:3667) is used as the acylating agent and N-methylimidazole or pyridine is used as the solvent.

-65-

2.7 2,6-diaminopurine riboside

The N-2,N-6-bis(9-fluorenylmethoxycarbonyl) derivative of 2,6-diaminopurine riboside is prepared by the general procedure.

5 The N-2,N-6-bis(isobutyryl) derivative is prepared by the general procedure.

2.8 2,6-diaminopurine-2'-deoxyriboside

10 The bis N-2,N-6-(9-fluorenylmethoxycarbonyl) derivative of 2,6-diaminopurine-2'-deoxyriboside is prepared by the general procedure.

2.9 Thioquanosine

15 The N-2 9-fluorenylmethoxycarbonyl derivative of thioguanosine is prepared by the general procedure.

2.10 2'-Deoxythioquanosine

20 The N-2 9-fluorenylmethoxycarbonyl derivative of 2'-deoxythioguanosine is prepared by the general procedure.

Example 3

Preparation of 5'-amino-2',5-dideoxyribonucleoside subunits.

25 Carbon tetrabromide, sodium azide, p-toluenesulfonyl chloride (tosyl chloride), triphenyl phosphine and 10% palladium on carbon are purchased from Aldrich Chem Co. Lithium azide is obtained from Kodak Laboratory and Specialty Chemicals.

30

3.1 General Method

The nucleosides employed in this example are thymidine, N6-benzoyl-2'-deoxyadenosine, N4-benzoyl-2'-deoxycytidine, and 2'-deoxyinosine.

-66-

2-hydroxy-pyrimidine-2'-deoxyriboside and the N2-N6-bisisobutyryl derivative of 2,6-diamino purine-2'-deoxyriboside (see Example 1). The required dried nucleoside (1 mmol) is weighed into a reaction 5 vessel containing triphenyl phosphine (1.01 mmol) and lithium azide (5 mmol). After the solids are suspended in DMF, carbon tetrabromide (1.0 mmol) is added to the vessel. The solution is stirred at room temperature for 24 h. After quenching the reaction with methanol, the 10 solution is evaporated to dryness. The residue is chromatographed on silica gel eluting with methanol/chloroform mixtures to afford the desired 5'-azido-2', 5'-deoxynucleoside.

The 5'-azido nucleoside (1 mmol) is dissolved 15 in ethanol. Hydrogenation in the presence of 10% palladium on carbon (catalytic amount) under a hydrogen atmosphere (35 psi) occurs over 10 h. The solution is filtered and evaporation under reduced pressure affords a crude solid. The solid is purified by trituration 20 with the appropriate solvent.

3.2 5'-Azidouridine derivative

The 5'-azido derivative of 5-bromo-2'-deoxy uridine is prepared via the method described above. The 25 5'-azido-5-bromo-2'-deoxyuridine (1 mmol) is treated with triphenyl phosphine (1.5 mmol) in pyridine at room temperature for 2 h. Concentrated ammonia (1 mL) is added to the reaction vessel. After 14 h the solvent is removed under vacuum. The residue is dissolved in THF 30 and this solution is added to hexanes. The precipitate is collected and the solid triturated with the appropriate solvent to afford the 5'-amino-5-bromo-2'-deoxyuridine.

-67-

3.5 5'-Azido guanosine

An alternate preparation of 5'-amino-2',5'-dideoxyguanosine is to treat the protected 2'-deoxyguanosine (protected at either the N-2-acetyl or the N-2-FMOC derivative) (1 mmol) with tosyl chloride (1.3 mmol) in pyridine at 0°C overnight. The solution is evaporated to dryness and the residue is dissolved in chloroform. The resulting solution is washed twice with aqueous sodium bicarbonate and dried over sodium sulfate. The solvent is evaporated and the residue chromatographed on silica gel eluting with methanol/chloroform mixtures. The resulting tosylate (1 mmol) is treated with sodium azide (6 mmol) in DMF at 80-100°C for a few h. The solvent is removed by rotovap and the residue is chromatographed on silica gel eluting with chloroform/methanol solvent mixtures. The azide is reduced to the desired amine using the above procedure.

Alternate protecting groups for the base nitrogens of 2'-deoxycytidine, 2'-deoxyadenosine, 2'-deoxyguanosine, and 2,6-diaminopurinedeoxyriboside are 2-(phenylsulfonyl)ethoxycarbonyl for 2'-deoxycytidine and 2'-deoxyadenosine and the use of the 9'-fluorenylmethoxycarbonyl (FMOC) to protect 2'-deoxyguanosine and 2,6-diaminopurine deoxyriboside, as in Example 2.

Example 4

Preparation of 3'-amino-2',3'-dideoxyribonucleoside subunits.

Thymidine is transformed to 5'-O-acetyl-3'-azido-2',3'-dideoxythymidine and this is converted to 3'-azido-2',3'-dideoxyadenosine and 3'-azido-2',3'-dideoxyguanosine via the methods of M. Imazawa and F. Eckstein, J Org Chem (1978) 43:3044. The base moiety of

-68-

the 3'-azidoadenosine is protected as either the benzoyl or the 2-(phenylsulfonyl)ethoxycarbonyl derivative (as shown in Example 1). N-2 of the 3'-azidoguanosine is protected as either the acetyl or FMOC derivative (see 5 Example 1). The reduction of these 3'-azido functions to the 3'-amino-2',3'-dideoxyribonucleosides is performed as shown in Example 3.

Example 5

10 Preparation of morpholino-type subunits derived from ribonucleosides.

Ammonium baborate, sodium m-periodate, sodium cyanoborohydride, uridine, N4-benzoyl cytidine, and N6-benzoyl adenosine are obtained from Sigma Chemical Co. N2-isobutyryl guanosine is prepared by the general method of Letsinger and Miller (J Amer Chem Soc (1969) 91:3356). 2-Phenyl-2-propanol and bis(p-nitrophenyl) carbonate are obtained from Aldrich Chemical Co.

The morpholino derivative of uridine is 20 prepared by dissolving 1 mmol of uridine plus 2 mmol of ammonium baborate, $(\text{NH}_4)_2\text{B}_2\text{O}_7$, in 5 ml of water. While stirring in an ice bath protected from direct light 1.2 mmol of sodium m-periodate in 5 ml of water is added. After 90 min, 0.2 ml of 1,2-propanediol 25 is added and stirring is continued for 10 min at rt. Thereafter, while stirring in a well-ventilated hood, 0.25 g of sodium cyanoborohydride dissolved in 3 ml of water is added and the mixture stirred for 4 hr at rt. Thereafter, the reaction mixture is reduced to an oil 30 under vacuum in a warm water bath, resuspended in a minimal volume of methanol, layered on a silica gel chromatography column, and the column eluted with methanol/1% triethylamine. The morpholino product elutes from the column as a sharp band moving

-69-

significantly slower than the original ribonucleoside and its oxidation products. The morpholino product has a UV spectrum essentially identical to the parent ribonucleoside, but its mass is lower by 17 daltons
5 (determined by mass spectral analysis using fast atom bombardment activation).

The morpholino nitrogen is next protected by reacting the product with 2-phenylisopropyl phenyl carbonate. The required active carbonate is prepared
10 and reacted with the morpholino subunit essentially by the methods of Sandberg and Ragmarsson (Int J Peptide Protein Res (1974) 6:111). Finally, if desired (depending on the method to be used for subunit assembly into polymers) the hydroxyl at the position
15 corresponding to the original 5' can be activated by dissolving the N-protected subunit in a minimal volume of dry dimethylformamide and adding 2 equivalents of bis(p-nitrophenyl)carbonate plus 0.2 equivalent of triethylamine, N-methyimidazole, or N,N-dimethylamino
20 pyridine. After 3 h at rt, the reactions mixture is reduced in volume under vacuum in a warm water bath. The thick syrup is resuspended in a small volume of dichloromethane and layered on a silica gel column, which is subsequently eluted with a mixture of
25 dichloromethane/ether (1:1 by vol) 0.2% in N,N-dimethylaniline by volume. With this solvent system, the activated product moves substantially slower than p-nitrophenol and bis(p-nitrophenyl)carbonate but much faster than the unreacted starting material. The
30 activated product is readily visualized on silica gel TLC plates simply by exposing to ammonia fumes, whereupon a yellow nitrophenolate ion is generated within one to two minutes.

-70-

Other ribonucleosides (bases protected where necessary as in Example 2) are converted to their corresponding morpholino derivatives by essentially the same methods -- though varying amounts of methanol must 5 be added to effect dissolution of the protected ribonucleosides before the initial periodate oxidation step.

When the morpholino-type subunits are to be coupled via thiocarbamate linkages, the preferred 10 base-protective groups for the common starting ribonucleosides are: the phenylsulfonylthioxycarbonyl moiety for cytidine and adenosine and the 9-fluorenyl methoxycarbonyl moiety for guanosine.

15

Example 6

Preparation of 5'-acetic acid-2',5'-dideoxyribonucleotide subunits.

Triethylamine, pyridine/sulfur trioxide complex, p-nitrophenol, dicyclohexylcarbodiimide, and 20 40% aqueous dimethylamine are obtained from Aldrich. 3'-O-tert-Butyldimethylsilyl-N-2-(phenylsulfonyl) ethoxycarbonyladenosine (1 mmol), prepared as in Example 12.1, is dissolved in methylene chloride and dimethylsulfoxide (10 mL, 1/1, v/v) at 0°C and 25 triethylamine (3 mmol) and the pyridine/sulfur trioxide complex (3 mmol) is added. The mixture is stirred at this temperature for 1 h, then washed with water, dried over sodium sulfate, and evaporated under reduced pressure. The residue is dissolved in dry pyridine (10 mL) and treated with 30 benzyloxycarbonylmethylenetriphenylphosphorane (1.5 mmol) for 24 h at 37°C. The mixture is then evaporated to dryness under reduced pressure and the residue dissolved in methylene chloride, washed with dilute HCl

-71-

and water, then the organic phases are dried over sodium sulfate and solvent removed under reduced pressure. The residue is chromatographed on silica using a gradient of methanol in chloroform (0-20%).

5 The unsaturated ester (1 mmol) from the previous paragraph is dissolved in ethyl acetate/ethanol (40 mL, 1/1, v/v) containing cyclohexadiene (5 mL) and 10% palladium on charcoal (100 mg) and the suspension is vigorously agitated under a nitrogen atmosphere for 5-24
10 h. The mixture is filtered and the solvents removed under reduced pressure. The residue is chromatographed on silica gel using a gradient of methanol in chloroform (5-50%).

To a 0.2-0.5 M solution of the acid from the previous paragraph in ethyl acetate (or methylene chloride) p-nitrophenol is added in about 20% excess. The calculated amount of dicyclohexylcarbodiimide is added to the solution at 0°C. After 0.5 h the mixture is allowed to come to room temperature and was held
20 there for 1 h. The dicyclohexylurea which separated is filtered and washed with solvent. The combined filtrate and washings are evaporated to dryness under reduced pressure. The ester may be used directly for coupling reactions or may be purified by short column
25 chromatography on silica using an isopropanol in chloroform gradient (0-50%).

The analogous series of reactions may be carried out on the other properly protected 2'-deoxynucleosides.

30 The active ester (1 mmol) is treated with 40% aqueous dimethylamine (2 mmol) in methanol to form the N,N-dimethylamide of the N-protected 3'-O-tert-butyl dimethylsilyl-2',5'-dideoxyadenosine-5'-acetic acid. The solvents are removed by evaporation under reduced

-72-

pressure and the residue is desilylated by using the 2M HF/1M tert-butylammonium fluoride (TBAF) reagent described in B.L. Gaffney and R.A. Jones, Tetrahedron Lett (1982) 23:2257. To the 2M HF/1M tert-butylammonium fluoride in pyridine (1 mmol of TBAF) is added the deprotected nucleoside from the previous paragraph. After stirring for 24 h the reaction is partitioned between methylene and aqueous sodium bicarbonate. The organic layer is washed with water, dried over sodium sulfate, and evaporated to dryness. The residue is purified by chromatography on silica using a gradient of methanol in methylene chloride (5-25%).

Example 7

15 Preparation of Purine and Pyrimidine Pyrrolidones

Potassium t-butoxide, anisoyl chloride, 6-chloropurine, 10% palladium on charcoal, phthaloyl chloride, 2-amino-6-chloropurine, 20% aqueous tetraethylammonium hydroxide, 25% aqueous trimethylamine, 2-pyrimidinone, N-bromosuccinimide, trifluoroacetic acid, 4-nitrophenol, and N,N-disuccinimidyl carbonate are obtained from Aldrich. Lithium azide is obtained from Eastman Kodak, Rochester, New York. C18 reverse phase silica gel is obtained from 25 Whatman, Hillsboro, Oregon.

7.1 Preparation of (S)-5-[(4-amino-2-oxopyrimidinyl)-methyl]pyrrolidone (henceforth referred to as the cytosine pyrrolidone)

30 Cytosine (2.2 mmol) is dissolved in dimethyl sulfoxide (2 mL) which contained potassium tert-butoxide (2 mmol). This solution is added to a flask which contained (S)-5-(tosyloxymethyl)-2-pyrrolidone (1 mmol, prepared by the procedure of E. Hardegger and H. Ott,

-73-

Helv Chim Acta (1955) 38:312). After dissolution, the mixture is stirred at 25°C for 6 h. The mixture is neutralized with acetic acid (2 mmol) and evaporated under reduced pressure. The residue is taken up in 5 dimethyl formamide (5 mL) and evaporated under reduced pressure, and this procedure repeated three times.

7.2 Preparation of N-4 anisoylcytosine pyrrolidone

The mixture from the previous paragraph is 10 dissolved in pyridine or N-methylimidazole (10 mL) and treated with anisoyl chloride (2.8 mmol) at room temperature. After stirring for 2 h, the mixture is quenched with ice (0.5 g). After 5 min, 1 mL of 29% ammonia was added. After 15 min at rt the solution is 15 dissolved in ethyl acetate (15 mL) and washed twice with brine (15 mL). The washings are combined and washed with ethyl acetate (2 x 30 mL), the combined organic layers dried with sodium sulfate and evaporated under reduced pressure. The residue is coevaporated several 20 times with toluene and the residue chromatographed on silica gel with a gradient of methanol in methylene chloride (0-20%).

7.3 Preparation of 6-chloropurine pyrrolidone

This compound is prepared as for the alkylation 25 of cytosine except that the alkylation is performed on 6-chloropurine and the mixture was heated at 35-95°C for several h. The mixture is cooled to room temperature, neutralized with acetic acid (2 mmol) and evaporated 30 under reduced pressure, shaken with a mixture of 20% methanol/chloroform and 10% sodium bicarbonate. The aqueous layer is washed with chloroform, the combined organic layers aree dried over sodium sulfate and evaporated under reduced pressure. The residue is

-74-

chromatographed on silica gel using a gradient of methanol in chloroform (0-25%).

7.4 Preparation of 6-azidopurine pyrrolidone

5 The 6-chloropurine pyrrolidone (1 mmol) is treated with lithium azide (2 mmol) in dimethyl sulfoxide (2 mL) at 30-100°C for several h. At the end of this time the mixture is evaporated under reduced pressure, dissolved in chloroform, washed with 10% sodium bicarbonate, and the organic layer dried over sodium sulfate and concentrated under reduced pressure. 10 The residue is chromatographed on silica using a gradient of methanol in chloroform (0-25%).

15 7.5 Preparation of adenosine pyrrolidone

The azide from the previous example is hydrogenated by shaking the azide (1 mmol) with 30 pounds of hydrogen pressure in a solution of ethanol (10 mL) containing palladium on charcoal (100 mg, 10% by weight Pd) for 24 h. The solution is filtered through celite and the solvent evaporated. The residue is used directly for the next step.

7.6 Preparation of N-6 phthaloyladenosine pyrrolidone

25 The phthaloyl group is introduced at the N-6 position by the acylation of the adenosine pyrrolidone (1 mmol) with phthaloyl chloride (1.4 mmol) using the procedure above for the anisoylation of cytidine except that no ammonia was added in the workup.

30

7.7 Preparation of 2-amino-6-chloropurine pyrrolidone

The pyrrolidone tosylate is alkylated with 2-amino-6-chloropurine as per the preparation of the 6-chloropurine derivative.

-75-

7.8 Preparation of quanine pyrrolidone

The chloropurine pyrrolidone (1 mmol) from the previous paragraph is dissolved in diglyme (10 mL) and 25% aqueous trimethylamine (2 mL). The solution is 5 stirred at rt for 5 h, water (10 mL) is added, and the mixture concentrated to 10 mL under reduced pressure. Acetic acid (2 mL) is added, and the mixture was evaporated under reduced pressure to an oil. The residue which contains tetraethylammonium acetate is 10 used directly for the next step.

7.9 Preparation of N-2 acetylguanine pyrrolidone

Guanine pyrrolidone (1 mmol) from the previous paragraph is reacted with acetic anhydride (5 mL) at 15 reflux for 2 h. The solvent is evaporated and the residue coevaporated with dimethylformamide. The residue is dissolved in methanol (5 mL) saturated with ammonia at 0°C, and the solution is stirred for 2 h at this temperature. The solvent is evaporated under 20 reduced pressure and the residue purified by chromatography on a short column of silica using a gradient of methanol in chloroform (5-50%).

7.10 Preparation of 2-amino-6-azidopurine pyrrolidone

25 This compound is prepared from the 2-amino-6-chloropurine pyrrolidone by use of the procedure of Example 7.4, except that the reaction requires longer times and was performed at a higher temperature.

30

7.11 Preparation of 2,6-diaminopurine pyrrolidone

This compound is prepared as for the adenosine pyrrolidone by reduction of the 2-amino-6-azido derivative.

5 -76-

7.12 Preparation of N-2 acetyl N-6 phthaloyl 2,6-diamino purine pyrrolidone

The acetyl group is introduced by the method above for N-2 acetylguanine pyrrolidone except that the 5 methanolic ammonia treatment is carried out for 8 h.

The solvents are evaporated and the residue is phthaloylated as for the adenosine derivative.

7.13 Preparation of inosine pyrrolidone

10 6-Chloropurine pyrrolidone (1 mmol) was converted to the inosine derivative by the method used for the preparation of the guanine pyrrolidone derivative. The compound is purified by chromatography on silica using a gradient of methanol in chloroform 15 (5-25%).

7.14 Preparation of 2-hydroxypyrimidine pyrrolidone

This compound is obtained by the alkylation of 2-pyrimidinone by the procedure used for the preparation 20 of the 6-chloropurine derivative.

Example 8

Preparation of Purine and Pyrimidine t-BOC Amino Acids

The general procedure described below for the 25 cytosine pyrrolidone may be applied to all properly protected pyrrolidone derivatives. The product, referred to as the t-BOC acid is formed by cleavage of the pyrrolidone ring to an acid and a t-BOC amine.

30 8.1 Preparation of the cytosine t-BOC acid

N-4-Anisoylcytosine pyrrolidone (1 mmol) is dissolved in methylene chloride (0.5 M solution) containing di-tert-butyl dicarbonate (2 mmol), triethylamine (1 mmol), and dimethylaminopyridine (1

-77-

mmol). The solution is stirred for 10 h at rt. The volatiles are removed and the residue purified on silica using a gradient of methanol in chloroform (0-20%). The residue is dissolved in tetrahydrofuran (0.2 M solution) 5 to which is then added lithium hydroxide (3 mmol, as a 1 M solut...n). After 5 h at rt, the solution is neutralized by the addition of 10% acetic acid (3 mmol) and the solvents removed under reduced pressure. The residue was dissolved in 9N ammonia and stirred at room 10 temperature for 1-10 h. The solvent is removed under reduced pressure and the residue purified by chromatography on C18 reverse phase silica gel using water and methanol (or trifluoroethanol) mixtures.

15 8.2 Preparation of uracil t-BOC acid

This is prepared from the cytosine t-BOC acid by the following procedure:

The cytosine t-BOC acid (1 mmol) is dissolved in aqueous acetic acid and treated with sodium nitrite 20 (1 mmol) at 4°C. The mixture is stirred for 1 h and evaporated to dryness under reduced pressure. The product is purified by chromatography in C18 reverse phase silica gel using water and methanol (or trifluoroethanol) mixtures.

25

8.3 Preparation of 5-bromouracil t-BOC acid

This compound is obtained from the uracil t-BOC acid by the following procedure:

The uracil t-BOC acid (1 mmol) is dissolved in 30 DMF (3 mL) and treated with N-bromosuccinimide (1.2 mmol). The solution is allowed to stand at room temperature for 16 h. After removal of the solvents under reduced pressure the product is purified by

-78-

chromatography on C18 reverse phase silica gel using water and methanol (or trifluoroethanol) mixtures.

8.4 Preparation of N-protected t-BOC acid

5 This general procedure for acylating the exocyclic amino groups of the recognition moiety is also applicable to the protection of the adenosine derivative.

10 The cytosine t-BOC acid (1 mmol) from the previous paragraph is dissolved in N-methylimidazole or pyridine (5 mL) and treated with chlorotrimethylsilane (5 mmol). After 15 min at room temperature the solution is treated with 2-(4-nitrophenyl)ethylchloroformate (3 mmol, obtained from F. Himmelsbach and W. Pfleiderer, Tetrahedron Lett (1983) 24:3583). The reaction is maintained at room temperature for 8 h, then cooled in an ice bath, and water (1 mL) was added. After 5 min, 1 mL of concentrated ammonia is added and the mixture stirred at rt for 15 min. The reaction is then evaporated to dryness and the residue dissolved in water. The solution is made acidic with 2 M HCl and extracted with chloroform. The combined organic extracts are dried over sodium sulfate and evaporated under reduced pressure. The residue is purified by chromatography on silica using a gradient of methanol in chloroform (5-50%).

15 For protection of the guanine and 2,6-diaminopurine derivatives, the above procedure was modified so that the reaction was carried out in pyridine and the acylating agent was 9-fluorenylmethyl chloroformate.

-79-

Example 9

Preparation of Purine and Pyrimidine Amino Acids

The following procedure is applicable to all
the derivatives. It removes the t-BOC group and frees
5 the primary amino group of the backbone.

The t-BOC acid (1 mmol) was dissolved in 20%
trifluoroacetic acid in methylene chloride (5 mL) and
stirred at rt for 30 min. Toluene (3 mL) is added and
the solvents are evaporated under reduced pressure to
10 give the amino acid trifluoroacetate salt. This is used
directly for coupling reactions.

Example 10

Preparation of Subunits for Assembly
of Achiral Acyclic Polynucleotide Analogs

10.1 Preparation of the Cytidine Analog

Lithium boryhydride, di-tert-butyl dicarbonate
and bis(triphenylphosphine) palladium II chloride were
20 obtained from Aldrich Chemical Co., Milwaukee, WI.
2-Amino-5-bromopyrimidine is prepared as per T.
Nishikawa, Chem. Pharm. Bull., 9:38 (1961).

2-amino-5-bromopyrimidine is benzoylated at the
exocyclic amino group by the general method in Example 2
25 using benzoyl chloride. The product benzamide (25
mmole) is added to a 45 mL pressure vessel containing
triethylamine (10 mL), benzene (10 mL), and
bis(triphenylphosphine) palladium II chloride (0.375
mmole). The bomb is flushed with argon, sealed, and
30 pressurized to 600 psi with carbon monoxide and then
pressurized to 1200 psi with hydrogen. The reaction
vessel is heated in an oil bath with stirring at 145°C.
after all gas absorption had ceased, the reaction is
cooled, and the gases vented slowly. After addition of

-80-

anhydrous ether, the reaction mixture is filtered and evaporated in vacuo. The product was isolated following chromatography in silica gel using a gradient of isopropanol in methylene chloride (0-20%).

5 The 2-benzamidopyrimidine-5-carboxaldehyde (1 mmol) from the previous paragraph is dissolved in ethanol (5 mL) and treated with 4-aminobutyric acid (1 mmole) and triethylamine (1 mmol). After stirring for one hour, the mixture is hydrogenated at 30 psi using
10 10% palladium on carbon (100 mg). After the absorption of hydrogen has ceased, the reaction is filtered and the solvents removed under reduced pressure. The residue is dissolved in methanol which is saturated with ammonia at 0°C and stirred at room temperature for 10 h. After
15 evapoaration of the solvents, the residue iss purified by chromatography on C18 silica gel using methanol water mixtures buffered to pH 7 with ammonium acetate (0.2 M).

The amino acid (1 mmol) from the previous paragraph is dissolved in ethanol (3 mL) containing
20 di-tert-butyl dicarbonate (1 mmol). Triethylamine (1.5 mmol) is added slowly at room temperature. After the evolution of carbon dioxide has ceased, the solvents are removed in vacuo and the residue used directly for the next reaction.

25 The t-BOC-amino acid from the previous paragraph is acylated on the exocyclic amino group by the general procedure in Example 2 using 2-(phenylsulfonyl)-ethoxycarbonyl chloride. The product may be purified by chromatography on silica gel using a
30 gradient of methanol in chloroform (0-50%).

The 2-(phenylsulfonyl)-ethoxycarbonyl-protected BOC amino acid from the previous paragraph was converted into the p-nitrophenyl or N-hydroxysuccinimidoyl active ester by the procedures in Examples 11.3 and 11.4.

-81-

10.2. Preparation of the Uridine Analog

Ethyl 6-hydroxynicotinate is prepared as per H. Gault, J. Gilbert, and D. Briaucourt, C.R. Acad. Sci., Paris, Ser. C, 266:131 (1968). Lithium borohydride is obtained from Aldrich. Manganese dioxide is prepared as per Vereshchagin et al, Zhurnal Organicheskoi Khimii, 8:1129 (1972). Dowex resin is obtained from Bio-Rad Laboratories, Richmond, CA.

Ethyl 6-hydroxynicotinate (49 mmole) in
10 tetrahydrofuran (10 mL) is added dropwise to a suspension of lithium borohydride (100 mmol) in tetrahydrofuran (THF) (75mL) at room temperature under nitrogen. The viscous mixture is stirred at 25°C for 16 hours. Then, 60 mL of 20% acetic acid is added to the cooled suspension. The THF is evaporated under reduced pressure and the remaining aqueous solution is applied to an ion exchange column (Dowex-50W-X8) to remove lithium ion. The column is washed carefully with 250 mL of water, which is then evaporated. Boric acid is
15 removed from the resulting residue by repeated evaporation with methanol. The product is purified by distillation under reduced pressure.

The benzylic alcohol (66 mmol) prepared in the previous paragraph is dissolved in ether (250 mL) and
25 treated slowly (exothermic) with a slurry of manganese dioxide (54 g) in ether (100 mL). After twelve hours at room temperature, the mixture is filtered, the solvent removed under reduced pressure, and the residue distilled in vacuo to give 6-hydroxynicotinaldehyde.

30 The aldehyde from the previous paragraph is reacted with 4-amino butyric acid as for the preparation of the cytidine analog in Example 11.1

-82-

The amino acid from the previous paragraph was converted to the corresponding BOC-derivative as for the preparation of the cytidine analog in Example 10.1

The BOC-amino acid from the previous paragraph
5 is converted into the p-nitrophenyl or
N-hydroxysuccinimidoyl active ester by the procedures in
Example 11.3 and 11.4.

Example 11

10 Preparation of 5'-protected, 3'-activated
2'-deoxynucleo- sides.

11.1 2'-deoxynucleoside 5'-O-dimethoxytrityl
derivatives

15 The procedure below is general for the preparation of 2'-deoxynucleoside 5'-O-dimethoxytrityl derivatives:

N-2 9-Fluorenylmethoxycarbonyl-2'-
deoxyguanosine (1 mmol) is dissolved in anhydrous
20 pyridine (2.0 mL) and kept at 0°C. Dimethoxytrityl
chloride (1.2 mmol) is added in portions (0.15 mmol)
during an 8 hour period. After an additional 2 hours
methanol (0.5 mL) was added and the solution is
concentrated at reduced pressure. The residue is
25 treated with a mixture of sodium bicarbonate (2 mL, 5%)
and methylene chloride (5 mL).

The aqueous layer is extracted with methylene
chloride (2x5 mL) and the combined organic layers are
dried over sodium sulfate and evaporated. The residue
30 is coevaporated several times with toluene and the
product is purified by chromatography on silica gel
using a gradient of methanol in methylene chloride
(0-10%).

-83-

11.2 5'-O-dimethoxytrityl-2'-deoxynucleoside
3'-O-(4-nitrophenyl)carbonates.

The preparation of 5'-O-dimethoxytrityl-2'-deoxycytidine 3'-O-(4-nitrophenyl)carbonates is described in the following procedure which is general for the preparation of the 4-nitrophenylcarbonates. Bis(4-nitrophenyl)carbonate and N,N-dimethylaminopyridine are obtained from Sigma.

5' O-Dimethoxytrityl-N-2-(4-nitrophenyl)-ethoxycarbonyl-2'-deoxycytidine (1 mmol) is dissolved in anhydrous dimethylformamide (5 mL) at room temperature and treated with bis(4-nitrophenyl)carbonate (2 mmol) and then evaporated under reduced pressure. The residue is dissolved in dimethylformamide (5 mL) and N,N-dimethylaminopyridine (0.1 mmol) is added. The yellow solution is evaporated and allowed to react for 1 h. The reaction mixture is dissolved in chloroform (10 mL) and washed with aqueous HCl (5 mL, 0.1 M). The organic layer is washed twice with aqueous NaOH (5 mL, 0.1 M), water (2 mL), dried over sodium sulfate and evaporated. The residue is applied to a silica gel column and eluted with a gradient of isopropanol in chloroform (0-10%). The fractions containing the product are pooled, evaporated, dissolved in chloroform (10 mL) and the aqueous NaOH washes are repeated to remove traces of 4-nitrophenol. The organic layer is washed with water, dried over sodium sulfate and evaporated. The product is homogeneous by TLC and is used directly for preparation of the dimeric carbonates.

For the preparations of the carbonates of nucleosides containing the FMOC group it is sometimes advantageous to use N-methylimidazole as the catalyst rather than N,N-dimethylaminopyridine.

-84-

11.3 N-protected t-BOC p-nitrophenyl ester

The following two procedures prepare active esters for coupling of subunits. It is general for all the t-BOC acid derivatives.

- 5 To a 0.2-0.5 M solution of the t-BOC acid from Example 8.4 in ethyl acetate (or methylene chloride), p-nitrophenol is added in about 20% excess. The calculated amount of dicyclohexylcarbodiimide is added to the solution at 0°C. After 0.5 h the mixture is
10 allowed to come to rt and was held there for 1 h. The dicyclohexylurea which separated is filtered and washed with solvent. The combined filtrate and washings are evaporated to dryness under reduced pressure. The ester may be used directly for coupling reactions or may be
15 purified by short column chromatography on silica using an isopropanol-in-chloroform gradient (0-50%).

11.4 N-protected t-BOC N-hydroxysuccinimidoyl ester

- To a solution of the t-BOC acid from Example 8.4 (1 mmol) in acetonitrile (5 mL) is added pyridine (1 mmol) and N,N'-disuccinimidyl carbonate (1 mmol). The solution is stirred at rt for 3 h. The solvents are removed under reduced pressure and the residue dissolved in chloroform, the organic phase washed with 0.1 M HCl
25 and water, dried over sodium sulfate, and evaporated to dryness. The esters are sufficiently pure to be used directly.

Example 12

30 Formation of a carbonate intersubunit linkage.

The preparation of cytidyl-(3'-5')-cytidine carbonate is described in the procedures below. This is a general procedure for the formation of the carbonate intersubunit linkage and the deprotection of the

-85-

oligocarbonate. Note that the base protecting groups must be 2-(4-nitrophenyl)ethoxycarbonyl, 2-(phenyl sulfonyl)ethoxycarbonyl, or FMOC. Tert-butyl dimethylsilyl chloride is obtained from Aldrich.

5

12.1 Preparation of 2'-deoxynucleoside 3'-O-tert-butyldimethylsilyl derivatives.

The preparation of 3'-O-tert-butyldimethylsilyl-N-2-(4-nitrophenyl)ethoxycarbonyl-2'-deoxycytidine is 10 described in the following procedure which is a general procedure for the preparation of 2'-deoxynucleoside-3'-O-tert-butyldimethylsilyl derivatives:

To a stirred solution of 5'-O-dimethoxytrityl-N-4-(4-nitrophenyl)-ethoxycarbonyl-2'-deoxycytidine 15 (1 mmol) and imidazole (3.5 mmol) in dry dimethylformamide or tetrahydrofuran (10 mL) is added dropwise a solution of tert-butyldimethylsilyl chloride (3 mmol) in dry DMF (10 mL). The reaction is stirred for 1 h, quenched with ice, extracted with methylene 20 chloride, washed with water and dried over sodium sulfate. The organic layer is evaporated to dryness under reduced pressure and purified by chromatography over silica gel with methylene chloride as eluant.

To a solution of the 5'-O-dimethoxytrityl derivative from the previous paragraph (1 mmol) in methylene chloride (5 mmol) is added a solution of zinc bromide in methylene chloride (10 mL, 1 M) containing methanol (15 % v/v). The reaction mixture is stirred for 30 min, quenched with ice, and extracted with 30 methylene chloride. The organic layer is washed with water, dried over sodium sulfate, and evaporated to dryness under reduced pressure. The product is purified by chromatography over silica gel using a gradient of methanol in methylene chloride (0-10%).

-86-

5'-O-dimethoxytrityl-N-2-(4-nitrophenyl)ethoxy carbonyl-2'-deoxycytidine-3'-O-(4-nitrophenyl)carbonate (1.5 mmol) and 3'-O-tert-butyldimethylsilyl-N-4-(4-nitrophenyl)ethoxycarbonyl-2'-deoxycytidine (1 mmol) are dissolved in dimethylformamide (5 mL) and the solvent removed under reduced pressure. This is repeated two times. The residue is redissolved in dimethylformamide (5 mL) and treated with N,N-dimethylaminopyridine (0.5 mmol) or N-methylimidazole (1 mmol). The solvent is removed by evaporation under reduced pressure and the reaction allowed to sit overnight at rt. The residue is dissolved in chloroform (20 mL) and washed with aqueous HCl (2 mL, 0.1 M), water (2 mL), aqueous NaOH (2 x 2 mL, 0.2 M), water (2 mL), and the organic layer dried over sodium sulfate and evaporated. The residue is purified on silica gel using a gradient of isopropanol in chloroform (0-30%). The isolated product is homogeneous on TLC and by 400 MHz NMR.

The residue is desilylated by using the 2 M HF/1M tert-butyldimethylsilyl fluoride (TBAF) reagent described in B.L. Gaffney and R.A. Jones, Tetrahedron Lett (1982) 23:2257. To the 2M HF/1M tert-butyldimethylsilyl fluoride in pyridine (1 mmol of TBAF) is added the deprotected nucleoside from the previous paragraph. After stirring for 24 h, the reaction is partitioned between methylene chloride and aqueous sodium bicarbonate. The organic layer is washed with water, dried over sodium sulfate, and evaporated to dryness. The residue is purified by chromatography on silica using a gradient of methanol in methylene chloride (5-25%).

The 3'-hydroxydinucleoside carbonates are converted to the 3'-(4-nitrophenyl)-carbonates by the method in Example 11. These derivatives may be reacted

-87-

with the 5'-hydroxyl of a nucleoside or oligonucleoside carbonate to prepare higher order oligonucleoside carbonates.

5

Example 13

Formation of a carbamate intersubunit linkage.

Bis(p-nitrophenyl)carbonate, p-anisoyldiphenyl methyl chloride, N,N-dimethylaniline (DMA), and triethylamine are available from Aldrich Chemical Co.

10

The required

5'-amino-2',5'-dideoxyribonucleoside (employing acetyl or benzoyl groups for base protection where necessary) (1 mmol) prepared in Example 3 above, is treated with p-anisoyl diphenylmethyl chloride (1.2 mmol) in pyridine. After 12 h the solvent is evaporated and the residue is redissolved in chloroform. This solution is washed once each with aqueous NaHCO_3 and water, then dried over Na_2SO_4 . After evaporation of the solvent, the residue is chromatographed on silica gel eluting with chloroform/methanol/1% triethylamine mixtures.

The 5'-tritylated aminonucleoside (1 mmol) is evaporated twice from DMF, then treated with bis-(p-nitrophenyl)carbonate (2 mmol) in the presence of 25 triethylamine (or N,N-dimethylaminopyridine, or N-methyl imidazole)(catalytic amount) using DMF as the solvent. After 3 h, the solvent is evaporated and the residue dissolved in chloroform. This solution is washed twice with 0.01 N aqueous NaOH, once with water, then dried over Na_2SO_4 . The solvent is removed by rotovap and the residue is chromatographed on silica gel eluting first with a chloroform/0.1% DMA mixture, then with a chloroform/methanol/0.1% DMA solvent system. The appropriate fractions are combined and evaporated to

dryness. The residue is dissolved in a minimum of THF and this solution is added to an excess of hexanes. The precipitated activated nucleoside is collected by filtration and dried under vacuum.

- 5 The required 5'-aminonucleoside (1.1 mmol), as prepared in Example 3 above, is twice evaporated from DMF. The activated nucleoside (1 mmol) is added to the reaction vessel and the solids are dissolved in DMF. The solution is concentrated to a small volume and
10 allowed to stand overnight. The solvent is completely removed under vacuum and the resulting residue is dissolved in chloroform. This solution is twice washed with 0.01 N aqueous sodium hydroxide, once with water, then dried over solid sodium sulfate. The solvent is
15 removed by rotovap, and the residue is chromatographed on silica gel eluting with the appropriate methanol/chloroform/1% triethylamine solvent system. The fractions containing the dimer nucleoside are combined, then evaporated to dryness. The residue is
20 dissolved in a minimum of THF and this solution is added to hexanes. The precipitate is collected and dried under vacuum.

Example 14

- 25 Formation of a thiocarbamate intersubunit linkage.

N,N-dimethylaminopyridine (DMAP) is purchased from Aldrich Chemical Co.

Formation of the thiocarbamate intersubunit linkage of the 5'-aminonucleosides prepared in Example 3
30 is achieved in the same manner as described above in Example 13 with the following alterations in procedure. The 5'-aminonucleosides employed have as base-protecting moieties either 2-(phenylsulfonyl)ethoxycarbonyl (for deoxycytidine and deoxyadenosine) or 9-FMOC (for

-89-

guanosine and 2,6-diamino-2'-deoxyriboside) groups. The preparation of these molecules are described above (Example 3). Activation of the 5'-tritylaminonucleoside (1 mmol) is achieved with p-nitrophenylchlorothioformate 5 (as prepared by G Hilgetag and R. Phillipson, Monatsber Deut Akad Wiss Berlin (1964) 6:897) (1.2 mmol) in the presence of triethylamine (2 mmol) and the DMAP (catalytic amount) in DMF. The coupling step employs this activated monomer (1 mmol) with the requisite 10 5'-aminonucleoside (1.1 mmol) using DMAP or N-methyl imidazole as catalyst and DMF as the solvent. In this aqueous workup of these steps, the 0.01 N aqueous NaOH washes are omitted, employing in their place water washes.

15

Example 15

Formation of carbamate and thiocarbamate intersubunit linkages between morpholino type subunits.

N-methylimidazole is purchased from Aldrich 20 Chemical Co.

The requisite dry, N'-protected, 5'-free alcohol morpholino type nucleoside (employing acetyl or benzoyl groups for base protection where necessary) 25 (1 mmol), prepared in Example 5 above is treated with bis-(p-nitrophenyl)carbonate and triethylamine (or DMAP or N-methylimidazole) (catalytic amount) in DMF under anhydrous conditions. The solution is stirred for 3 h, then evaporated to dryness. The residue is dissolved in chloroform and the solution is washed twice with 0.01 N aqueous NaOH, once with water, then dried over 30 Na_2SO_4 . The solvent is removed by rotovap and the residue is chromatographed on silica gel eluting with an appropriate chloroform/isopropanol/0.1% DMA mixture. The fractions containing the desired activated

-90-

nucleoside are combined, evaporated, and the resulting solid is dissolved in a minimum of THF. The THF solution is added to an excess of hexanes and the resulting precipitate is collected and dried.

- 5 The required 5'-free hydroxy, N'-free morpholino type nucleoside (using the identical base protecting groups listed above in this example) (1.1 mmol), after evaporation twice from DMF, is treated with the 5'-(*p*-nitrophenoxy carbonyl)morpholino subunit (1 mmol) in DMF. The volume of the reaction solution is reduced under vacuum to a small volume. If required, a catalytic amount of N-methylimidazole or triethylamine is added to the reaction vessel. The resulting solution is allowed to stand overnight at rt. The remaining solvent is evaporated, and the residue is dissolved in chloroform. The chloroform solution is washed twice with 0.01 N aqueous NaOH, once with water, and then dried over Na_2SO_4 . The solvent is removed by rotovap and the residue is chromatographed on silica gel 10 eluting with chloroform/methanol solvent mixtures. The fractions containing the desired dimer are combined, then rotovaped to dryness. The residue is dissolved in a minimum of THF and the solution is added to an excess of hexanes. The precipitate is collected and dried 15 under vacuum.

- Morpholino subunits linked by thiocarbamate moieties are prepared as related above in this example with the following experimental alterations. The base-protecting groups are either 20 1-(phenylsulfonyl)ethoxycarbonyl (for deoxycytidine and deoxyadenosine) or 9-FMOC (for deoxyguanosine and 2,6-diamino-2'-deoxyriboside) groups. The preparation of these molecules is described above (Example 5). Activation of the N-protected morpholino nucleoside 25

-91-

(1 mmol) is achieved with p-nitrophenylchlorothioformate (1.2 mmol) in the presence of triethylamine (2 mmol) and DMAP or N-methyl imidazole (catalytic amount) in DMF. The coupling step employs this activated monomer (1 mmol) with the requisite N'-free morpholino nucleoside (1.1 mmol) using DMAP or N-methyl imidazole as catalyst and DMF as the solvent while warming the solution to 35-40°C. In the aqueous workup of these steps, the 0.01 N aqueous NaOH washes are omitted, employing in their place water washes.

Example 16

Preparation of an ester subunit linkage.

N,N-dimethylaminopyridine and N-methylimidazole are obtained from Aldrich.

The coupling of two subunits is performed by reaction of the 5'-N,N-acetamide-3'-hydroxy derivative with the 3'-silylated-5'-active ester. These are prepared as in Example 6. The reagents (1 mmol each) are coevaporated several times with dimethylformamide, then dissolved in dimethylformamide (5 mL) and treated with N,N-dimethylaminopyridine (0.2 mmol) or N-methylimidazole (1 mmol). The solvent is removed under reduced pressure and the reaction allowed to stand at room temperature for 2 h. The residue is dissolved in chloroform and washed with dilute HCl, water, and the organic phase dried with sodium sulfate and solvents evaporated under reduced pressure. The residue is purified by chromatography on silica gel using a gradient of methanol in chloroform.

The chain may be elongated by desilylation as in Example 6, and treatment of the resulting 3'-free hydroxy compound with the active ester as in the previous paragraph.

-92-

Example 17

Formation of a t-BOC amide-linked dimer

A fully protected t-BOC N-hydroxysuccinimidoyl ester or p-nitrophenyl ester prepared as in Example 11.3 and 11.4 (1 mmol) is dried by several coevaporations with dry dimethylformamide. The protected amino acid trifluoroacetate salt from Example 9 (1 mmol) is treated similarly. The two components are separately dissolved in dry dimethylformamide (2 mL), mixed, and treated with diisopropylethylamine (1.0 mmol). The solution is stirred at room temperature for 1 h, then the solvent is removed by evaporation under reduced pressure, the residue dissolved in chloroform and washed with dilute HCl. The organic layer is dried over sodium sulfate, evaporated to dryness under reduced pressure, and the residue purified by chromatography on silica gel using a gradient of methanol in chloroform (5-50%). Alternatively the t-BOC dimer acid may be purified by chromatography on C18 reverse phase silica gel using water and methanol (trifluoroethanol) mixtures.

17.1 Preparation of the t-BOC dimer active ester

The acid from the previous paragraph is converted into the N-hydroxysuccinimidoyl ester or p-nitrophenyl ester by application of the general methods in Example 11.3 and 11.4.

17.2 Preparation of the t-BOC dimer amino acid trifluoro acetate

The t-BOC dimer acid is treated with trifluoro acetate as per the general procedure in Example 9.

-93-

17.3 Preparation of a t-BOC tetramer acid

The t-BOC dimer active ester and the dimer acid trifluoroacetate are coupled to the t-BOC tetramer acid by the general procedure. Purification is best effected
5 by chromatography on C18 reverse phase silica gel using water and methanol (or trifluoroethanol) mixtures buffered to pH 7.0 with triethylammonium acetate. In this manner chains of any length may be prepared by coupling an active ester with a free amine component.

10

Example 18

Geometric assembly of an 8-subunit carbamate-linked polymer

DEAE cellulose is purchased from Sigma Chemical
15 Co. Preparative TLC plates are a product of EM Science purchased from UWR Scientific. HPLC equipment, columns, and supplies are available from Beckman Instruments, Inc.

The requisite carbamate-linked dimer (0.2 mmol) prepared as described in example 12, is treated with 4
20 mL of a 1/1/1 mixture of methanol/THF/glacial acetic acid at rt for 12 h. The solvent is removed under vacuum and the residue is taken up in a minimum of THF. The THF solution is added to a large volume of hexanes and the resulting precipitate is collected and dried.
25 The acetate salt is dissolved in a 4/1 THF/ethanol mixture and DEAE cellulose (0.8 mmol of the base) is added to the vessel. After stirring for 20 min, the heterogeneous mixture is filtered and the filtrate evaporated to dryness. The residue is dissolved in a
30 minimum of 4/1 THF/ethanol and this solution is added to hexanes. The solid is collected and dried. The precipitation procedure is repeated once.

The required N-5'-trityl dimer (0.1 mmol) (as prepared in Example 12) is evaporated twice from DMF,

-94-

then treated with bis(p-nitrophenyl)carbonate (2 mmol) in the presence of triethylamine (or DMAP or N-methyl imidazole) (catalytic amount) using DMF as the solvent. after 3 h the solvent is evaporated and the residue 5 dissolved in chloroform. This solution is washed twice with 0.01 N aqueous NaOH, once with water, then dried over Na_2SO_4 . The solvent is removed by rotovap and the residue is chromatographed on silica gel eluting with a chloroform/isopropanol or methanol/0.1% DMA 10 mixture. The appropriate fractions are combined and evaporated to dryness. The residue is dissolved in a minimum of THF and this solution is added to an excess of hexanes. The precipitated activated dimer is collected by filtration and dried under vacuum.

15 The 5'-amino dimer nucleoside prepared above (0.11 mmol) is twice evaporated from DMF. The activated dimer (0.1 mmol) is added to the reaction vessel and the solids are dissolved in DMF. The solution is concentrated to a small volume and allowed to stand 20 overnight. The solvent is completely removed under vacuum and the resulting residue is dissolved in chloroform. This solution is twice washed with 0.01 N aqueous sodium hydroxide, once with water, then dried over sodium sulfate. The solvent is removed by rotovap 25 and the residue is chromatographed on a preparative TLC plate eluting with the appropriate methanol/chloroform/1% triethylamine solvent system. The band containing the tetramer nucleoside is eluted and the solvent is evaporated. The residue is dissolved 30 in a minimum of THF and this solution is added to hexanes. The precipitate is collected and dried under vacuum.

The following transformations are performed using the procedures enumerated above in this example.

95-

The requisite N-5'-trityl tetramer nucleoside (0.06 mmol) is treated with 1/1/1 THF/methanol/glacial acetic acid, then purified to afford the 5'-aminotetramer nucleoside. Another aliquot of the N-5'-trityl tetramer nucleoside (0.05 mmol) is activated with bis(p-nitro phenyl)carbonate and subsequently purified. The two tetramers are coupled, worked up, and further purification is achieved either by chromatography on a preparative TLC plate or by HPLC chromatography. The chromatographed material is isolated as a solid, dissolved in a minimum of THF, and then precipitated from hexanes. The octomer nucleoside is collected and dried.

The octamer is configured for further use as follows. The N-5'-trityl octomer nucleoside is treated with 1/1/1 THF/methanol/glacial acetic acid and purified employing the conditions listed above. The 5'-amino octomer nucleoside (0.01 mmol) is treated with succinic anhydride (0.02 mmol) in pyridine at room temperature for two hours. The solvent is removed by rotovap and the residue is evaporated several times from ethanol. The residue is taken up in 3/1 THF/ethanol and added to a 2/1 hexane/benzene mixture. The solid is collected and dried. The N-5'-succinylated octamer nucleoside (0.01 mmol) is treated with a 1/1 mixture of pyridine/concentrated ammonia (1 mL). After standing overnight the solvent is removed by rotovap and the residue is evaporated from ethanol several times. The crude solid is purified using reverse phase (RP-18) HPLC chromatography. The elutants are evaporated and the residue is taken up in DMSO and precipitated from a 1/1 hexane/benzene solvent mixture. The solid is collected and dried.

-96-

Example 19

Preparation of a support-bound cleavable linker suitable for stepwise and stepwise/block assembly of polymers: activation of support and attachment of linker.

- 5 Long-chain alkylamine-derivatized controlled pore glass (Cat. No. 24875) is obtained from Pierce Chemical Co. 2,2-sulfonyldiethanol and dicyclohexylcarbodiimide are obtained from Aldrich Chemical Co.
- 10 The amino groups of the glass support (approximately 40 mmol per gram of support) are reacted with succinic anhydride essentially by the method of Matteucci and Caruthers (J Amer Chem Soc (1981) 103:3185) to give free carboxylic acid termini.
- 15 One-tenth mol of 2,2'-sulfonyldiethanol (60 % by weight in water) is dried by mixing with three volumes of dimethylformamide (DMF), reducing to a thick syrup under vacuum in a warm water bath, adding a second quantity of DMF, reducing to a thick syrup, and repeating the
- 20 process a third time. Dry DMF is then added to give a final sulfonyldiethanol concentration of 2 M. A mixture of 1 ml of the sulfonyldiethanol solution plus 0.2 g of dicyclohexylcarbodiimide is added to 1 g of the dry controlled pore glass support carrying carboxylic acid
- 25 residues and the slurry mixed by rocking or tumbling (not stirring) overnight at rt. Thereafter, the glass support is thoroughly washed with methanol and dried.

-97-

Example 20

Preparation of a 14-subunit carbonate-linked polymer targeted against a conserved sequence in the AIDS viral genome: stepwise assembly on a solid support: addition 5 of the first subunit and chain extension.

N-methylimidazole,
4-(N,N-dimethylamino)pyridine (DMAP), and
1,8-diazabicyclo[5.4.0]undec-7-ene (DBU) are obtained
from Aldrich Chemical co. Methyl p-nitrophenyl
10 carbonate is prepared from methyl chloroformate and
p-nitrophenol.

The 2'-deoxycytidine subunit(0.1 mmol)
prepared as in Example 4.2 (wherein the N4 carries a
p-nitrophenethoxycarbonyl moiety, the 5' oxygen carries
15 a di(p-methoxy)trityl moiety (DMT), and the 3' oxygen
carries a p-nitrophenoxy carbonyl moiety) is dissolved in
a minimal volume of dry tetrahydrofuran (THF) or
dimethylformamide and added to 0.5 g of thoroughly dried
controlled pore glass support carrying a cleavable
20 linker, prepared as in Example 19. Catalyst (either 1
mmol of N-methylimidazole or 0.1 mmol of DMAP) is
introduced and the slurry is mixed by rocking or
trembling (not stirring) for 2 hours. The slurry is
next filtered, and the solid washed thoroughly with THF.

25 Any unreacted hydroxyls are capped by adding
two ml of THF 1 M in methyl p-nitrophenyl carbonate and
0.5 M in DMAP and mixing for 20 min at rt. Thereafter,
the glass support is washed with THF and filtered.

The dimethoxytrityl at the 5' terminus is then
30 removed by washing the support with dichloromethane
followed by treatment with 5 ml of 0.2 M dichloroacetic
acid in dichloromethane for 5 min at rt. The glass
support is next washed with dichloromethane and filtered.

98

Subsequent subunits, prepared as in Example 1 and activated as in Example 2, are added in a like manner and in the following order: G,A,T,A,A,C,A,T,T, T,T,T,C, (G protected with the Fmoc moiety, A and C 5 protected with the p-nitrophenethoxy carbonylmoiety).

Example 21

Preparation of a 19-subunit carbamate-linked polymer targeted against a conserved sequence in the AIDS viral genome. Stepwise assembly of oligomer blocks on a solid support: addition of the first subunit and chain extension.

The 5'-amino-2',5'-dideoxycytidine subunit (0.2 mmol), prepared as in Example 3 (wherein the N4 15 carries a benzoyl moiety, the 5'-amine carries a p-methoxytrityl moiety, and the 3' oxygen carries a p-nitrophenoxycarbonyl moiety) is dissolved in a minimal volume of dry THF and added to 0.5 g of dried controlled pore glass support carrying a cleavable linker, prepared 20 as in Example 19. Catalyst (either 1 mmol N-methylimidazole or 0.1 mmol of DMAP) is introduced and the slurry mixed by rocking or tumbling for 2 h. The slurry is next filtered, and the solid washed thoroughly with THF.

25 The mono-p-methoxy trityl is removed by washing with dichloromethane, followed by treatment with 5 ml of 0.2 M dichloroacetic acid in dichloromethane at rt for 1 min. The support is then washed with dichloromethane and filtered. The 5' amino termini are converted to 30 their free amine form by a brief wash with 3 ml of THF containing 1% by volume of diisopropylethylamine, followed by washing with THF and filtration.

0.1 mmol of 3' p-nitrophenoxycarbonyl-activated dimer having the sequence 5'-A-G-3', prepared as in

Example 13 (wherein the guanine N2 is protected with an acetyl moiety and the adenine N6 is protected with a benzoyl or a p-nitrobenzoyl moiety), is dissolved in a minimal volume of dry THF and added to the glass support 5 and mixing is carried out for 2 h (no catalyst is added for this and subsequent coupling steps). The slurry is next washed with THF and filtered.

Any unreacted amine moieties are capped by adding 2 ml of THF 2 M in p-nitrophenyl acetate and 10 mixing at rt for 20 min. Thereafter, the glass support is washed with THF and filtered.

The mono-methoxytrityl at the 5' terminus is removed with dichloroacetic acid, as before.

Subsequent activated dimeric subunits, prepared 15 as in Example 17 (wherein the exocyclic ring nitrogen of cytosine is protected with a benzoyl moiety and the exocyclic ring nitrogen of A is protected with a benzoyl or a p-nitrobenzoyl moiety), and added in a like manner and in the following order: A-T, C-A, T-A, T-T, T-T, 20 A-C, A-C, C-A (5' to 3').

Subunits having base exocyclic ring nitrogen protective groups removable by strong nonnucleophilic bases (e.g., p-nitrophenethoxycarbonyl or phenylsulfonyl ethoxycarbonyl for A and C, and Fmoc for G) can also be 25 used for assembling polymers by the procedure above. However, polymers having these alternative protective groups are generally deprotected by treatment with DBU rather than by ammonium hydroxide.

-100-
Example 22

Preparation of a 19-subunit amide-linked polymer targeted against a conserved sequence in the AIDS viral genome. Stepwise assembly of oligomer blocks on a solid support: addition of the first subunit and chain extension.

A cytosine-containing acyclic-backboned subunit (0.2 mmol), prepared as in Example 11.3 (wherein the N4 of the cytosine carries a 2(P-nitrophenyl)ethoxycarbonyl moiety, the amine of the backbone carries a t-butoxycarbonyl moiety, and the carboxyl is in the form of a p-nitrophenyl ester) is dissolved in a minimal volume of dry THF and added to 0.5 g of dried controlled pore glass support carrying a cleavable linker, prepared as in Example 19. Catalyst (either 1 mmol of N-methylimidazole or 0.1 mmol of DMAP) is introduced and the support mixed for 2 h, filtered, and the solid is washed thoroughly with THF.

The t-BOC is removed by washing the support 20 with dichloromethane followed by treatment at rt with 5 ml of 20% by volume trifluoroacetic acid in methylene chloride for 30 min. The support is washed with dichloromethane and filtered. The support-bound amino terminus is converted to the free amine form by a brief 25 wash with 3 ml of THF containing 1% by volume of diisopropylethylamine, followed by a THF wash.

The activated dimeric subunit (0.1 mmol) having the sequence (amino terminus)-G-A-(carboxy terminus) prepared as in Example 17 (wherein the N2 of guanine 30 carries an Fmoc moiety, the N6 of adenine carries a p-nitrophenethoxycarbonyl moiety, the backbone amino terminus carries a t-BOC moiety, and the carboxy terminus is in the form of a p-nitrophenyl ester) is dissolved in a minimal volume of dry THF and added to

-101.

the glass support and mixing is carried out for 2 h (no catalyst is added for this or subsequent coupling steps). The support is washed with THF.

Any unreacted amine moieties are capped by
5 adding 2 ml of 2 M p-nitrophenyl acetate in THF and
mixing at rt for 20 min. Thereafter, the glass support
is washed with THF.

The terminal t-BOC moiety is removed with TFA
and the support neutralized, as described above.

10 Subsequent dimeric subunits, prepared as in
Example 17, are added in a like manner in the following
order: (C-terminus) T-A, A-C, A-T, T-T, T-T, C-A, C-A,
A-C (N-terminus).

Subunits having exocyclic ring nitrogen
15 protective groups removable by good nucleophiles (e.g.,
benzoyl for C, benzoyl or nitrobenzoyl for A, and acetyl
or isobutyryl for G) can also be used for assembling
polymers by the above procedures. However, polymers
having these alternative protective groups are generally
20 deprotected by treatment with ammonium hydroxide rather
than by DBU.

Example 23

Preparation of Nucleoside

25 3'-O-(p-chlorophenyl-2-cyanoethyl)-phosphates

23.1 Preparing Nucleosides with a 3' protecting group

Thymidine, N-benzoyldeoxyadenosine,
N-benzoyldeoxycytidine, N-isobutyryldeoxyguanosine and
their 5'-O-(di-p-methoxytrityl) 5'-ODMT-nucleoside)
30 derivatives are obtained from Pharmacia P-L Biochemicals
(Piscataway, NJ). β -benzoylpropionic acid and
dicyclohexylcarbodiimide (DCCD), are obtained from
commercial sources.

-102-

A selected 5'-O-dimethoxytrityl nucleoside (1 mmol) is reacted with β -benzoylpropionic acid (3 mmol) and DCCD (4 mmol) in 6 ml pyridine. The reaction mixture is stirred at 25°C for three hours, after which 5 1.5 ml water is added and the mixture stirred for 5 hours at 25°C. The reaction mixture is filtered, and after evaporation of the filtrate, the residue is freed of pyridine by several coevaporations with ethanol. The purified residue is taken up in ethyl acetate and 10 chromatographed on silica gel using ethyl acetate. The concentrated ethyl acetate eluate is treated with hexane to precipitate the resultant 3'-O- β -benzoylpropionyl-nucleoside (3'-OB_B-nucleoside).

15 23.2 Nucleoside Activation

p-Chlorophenylphosphorodichloride is obtained from Aldrich (Milwaukee, WI). Benzenesulfonic acid, tetrahydrofuran, triethylamine, and 3-hydroxypropanenitrile are obtained from commercial sources.

20 A solution of p-chlorophenylphosphoro-ditriazolate is prepared by sequential reaction of 3 mmol triazole in 10 ml tetrahydrofuran with 3 mmol triethylamine and 1.5 mmol p-chlorophenylphosphoro-dichloride. After a 10-minute reaction at 25°C, 1 25 mmol of a selected 5'-ODMT nucleoside in 2 ml dry pyridine is added to the reaction mixture. After standing at 25°C for up to two hours, the mixture is treated with a solution of benzenesulfonic acid (4 mmol) and triethylamine (4 mmol) in 3 ml anhydrous pyridine, followed by addition of 3-hydroxypropanenitrile (2 30 mmol). The reaction mixture is concentrated to 4 ml under vacuum and kept at 25°C for up to 2 hours, then at 4°C for up to 24 hours. The reaction is terminated by pouring the mixture into 20 ml of 5% aqueous sodium

;

-103.

bicarbonate at 0°C, extracting thoroughly with chloroform, drying the extracts with sodium sulfate, and removing the solvents under reduced pressure. The 5'-ODMT nucleoside 3'-O-(p-chlorophenyl-
5 (2-cyanoethyl))-phosphate product is obtained by chromatography on silica gel using successive elutions of ether, ethyl acetate, and tetrahydrofuran.

10

Example 24Preparing a tetramer with alternating charged and uncharged bonds

Methylphosphonodichloride is obtained from Aldrich. Benzenesulfonyl tetrazlide is prepared according to Stawinski, et al, Nucleic Acids Research (1977) 4:353.

24.1 Dimer Synthesis

A solution of methylphosphonoditriazolide is prepared by reacting 1,2,4-triazole (3 mmol) and triethylamine (3 mmol) in 20 ml anhydrous tetrahydrofuran in the presence of methylphosphonodichloride (1.2 mmol) for 2-10 hours at 25°C. Following filtration, a solution of a selected 5'-ODMT nucleoside (1 mmol) in 10 ml dry pyridine is added to the filtrate, and the mixture is concentrated to 8 ml and allowed to stand at 25°C for up to 2 hours. To the solution is added benzenesulfonyl tetrazolide (1.2 mmol) and the selected 3'-OB_B nucleoside. After incubation for 2.5 hours at 25°C, the reaction is quenched by the addition of 20 ml of 50% sodium bicarbonate at -78°C and extracted thoroughly with chloroform. The solvent is dried with sodium sulfate and evaporated. The reaction may also be performed substantially as above beginning with the

-104

3'-O-PO-(OpCP)(OCE)-protected nucleoside phosphate from Example II.

24.2 Separating Stereoisomeric Methylphosphonate Dimers

The stereoisomeric dimers produced in the above section are separated by silica gel column chromatography, carried out at atmospheric pressure in glass columns with packed silica gel 60, using ethyl acetate:tetra-

hydrofuran mixtures (0-100% tetrahydrofuran) or chloroform/methanol mixtures (0-20% methanol). The faster moving stereoisomer fractions are combined, and precipitated from the tetrahydrofuran solution by the addition of hexane. The slower-moving stereoisomer is not used further.

24.3 Phosphodiester/Methylphosphonate-linked Tetramer

First and second stereospecific methylphosphonate dimers, each having a selected 2-base combination and 3' OBD and 5' ODMT protecting groups, are each prepared as in Examples 24.1 and 24.2. Mesitylenesulfonyl tetrazolate is prepared according to Stawinski, et al., *Nuc Acids Res* (1977) 4:353.

The 5' ODMT protecting group on the first dimer is removed to give the pure 5' hydroxy compound. The cyanoethyl group of the second dimer is removed by treatment of 1 mmol of the dimer with a solution of pyridine (8.5 ml), water (2.9 ml), and triethylamine (2.9 ml) for 1 hour at 25°C, and evaporating the solvents to give the 3' hydroxynucleotide.

The dimer condensation reaction is carried out by dissolving the 5'-OH dimer (1 mmol) and the 3'-hydroxynucleotide dimer (1 mmol) in 8 ml of pyridine

-105-

and treating with mesitylenesulfonyl tetrazolide (3-6 mmol) for 3.5 hours at 25°C. The reaction mixture is combined with 4 ml of cold 50% aqueous pyridine and poured into 80 ml of aqueous sodium bicarbonate. The reaction product is extracted thoroughly with chloroform, and after drying over sodium sulfate and evaporation of the organic solvent, is purified on silica gel using a methanol/chloroform mixture. The eluted product is precipitated with hexane. Tetramers possessing the 3'-O-PO-(OpCP)(OCE) protecting group may be prepared by substantially the same method beginning with a dimer possessing the 3'-O-PO-(OpCP)(OCE) group.

Example 25

15 Attachment of polymer to a solid support through a linker arm

25.1. Preparation of a bi-functional hexane linker arm
Dowex 50X pyridinium resin is obtained from
20 Bio-Rad (Richmond, CA), and 6-aminohexanol, dimethyl-formamide and 3-hydroxypropanenitrile are obtained from commercial sources. 6-(2-methylsulfonyl)-ethyl p-nitrophenyl carbonate is prepared according to Eberle, et al., Helvetica Chimica Acta (1975) 58:2106.

25 A bi-functional hexane linker arm 6-(2-(methylsulfonyl)-ethoxycarbonylamino)-hexanol is prepared by reacting 6-aminohexanol (1 mmol) with 2-(methylsulfonyl)ethyl p-nitrophenylcarbonate (1 mmol) in 1 ml dimethyl-formamide for up to 4 hours at 25°C. The reaction mixture is poured into water, extracted thoroughly with benzene, the benzene washed with water, and the organic solvent then dried with sodium sulfate and evaporated to give the carbamate alcohol, which is purified by silica

-106-

gel chromatography using a methanol/chloroform solvent mixture.

25.2 Preparation of an Oligonucleotide Analog

5 with a 5'-O-(6-aminohexyl) Linker Arm

Triethylammonium bicarbonate and tetrabutylammonium fluoride are obtained commercially. A fully protected oligonucleotide analog is prepared by the methylphosphonate-dimer condensation scheme 10 described in Example VI. The oligonucleotide (1 mmol) is dissolved in 10 ml of chloroform:methanol (7:3, v/v) containing 2% benzenesulfonic acid, and kept at 0°C for about 40 minutes. The reaction mixture is washed with a 5% sodium bicarbonate solution and then water. The 15 chloroform layer is dried over sodium sulfate, filtered, and evaporated under reduced pressure. The material is dissolved in chloroform, and the residue chromatographed on silica gel using chloroform/methanol mixtures to give the 5' hydroxy oligonucleotide compound.

20 A solution of 6-(2-(methylsulfonyl)-ethoxy-carbonylamino)-hexyl methylphosphonyl triazolide (5 mmol) in pyridine (10 ml) is prepared by treating the carbamate alcohol from Example 25.1 with methylphosphonoditriazolide, prepared as described in Example 24.1.

25 To the solution is added the 5' hydroxy compound (1 mmol) from the previous paragraph and benzenesulfonyl tetrazolide (4 mmol). The reaction is continued and worked up as for Example 24.1

The residue is chromatographed on silica gel 30 using a chloroform/methanol solvent mixture. The protected oligonucleotide (1 mmol) is treated with 4 ml hydrazine hydrate in 14 ml of 20% acetic acid/pyridine for 16-24 hours at 25°C. After evaporation, the residue is treated with a solution containing 0.017 M

-107

tetrabutylammonium fluoride in 30 ml tetrahydrofuran/pyridine/water (8:1:1, v/v/v) for 24 hours at 25°C. The solution is then treated with 60 ml 50% concentrated ammonium hydroxide in pyridine for 10 hours at 4°C. The 5 resulting oligomer is purified on a reverse-phase HPLC column using an aqueous acetonitrile mixture in 0.1 M ammonium acetate buffer, pH 5.8, as the chromatography solvent.

10 25.3 Attachment of a 5'-O-(aminohexyl)-
Oligonucleotide Analog to a Solid Support

Affi-gel 10 is obtained from Bio-Rad (Richmond, CA). 10 ml of the packed gel is washed with isopropyl alcohol (3 bed volumes), and then with ice-cold 15 deionized water (3 bed volumes). A 5'-O-(6-aminohexyl)- oligonucleotide (150 mmol) is prepared as described in Example 26. The oligonucleotide (150 M) in 5 ml 0.1 M sodium bicarbonate buffer, pH 8.0, is slurried with the washed gel for 1-4 hours at 25°C. The mixture is 20 then treated with 1 ml 1 M ethanolamine:HCl buffer, pH 8.0, to cap any unreacted active esters on the gel. The gel is washed with water until all the buffer has been removed, and stored at 4°C in the presence of 0.02% sodium azide.

25

Example 26

Preparation of the Reagent Support

Aminomethylated polystyrene is prepared as 30 described by B.A. Mukhitdinova, E.E. Eighozin, and G.A. Makhmudova, Izv Akad Nauk Kaz SSR., Ser Khim (1980) 48. Disuccinimidio dicarbonate and 6-aminohexanol are obtained from Aldrich.

-108.

- Aminomethylated polystyrene (1 g, 3.0 meq/g) is suspended in water/acetonitrile (10 ml, 3:1 v/v) and treated with succinic anhydride (20 mmol) at 4°C. The pH of the solution is kept at 6.0 by the addition of 20% NaOH. When the pH of the solution holds constant, the reaction is continued for 24 hours. The beads are filtered, washed with 2 N HCl, water (until the pH of the washings is neutral) and made anhydrous by repeated washings with dioxane.
- 10 The support (having bound acid groups) from the previous paragraph is reacted with disuccinimido carbonate (20 mmol) in acetonitrile (10 ml) for 24 hours at 25°C. The support is isolated by filtration and the support having bound succinimido ester is washed
- 15 thoroughly with acetonitrile.

The support from above is suspended in dimethylformamide (10 ml) and reacted with 6-amino-hexanol (20 mmol) for 24 hours at 25°C. The support is isolated by filtration and the support having the bound alcohol chain is washed thoroughly with dimethyl-formamide.

Example 27

Procedure for Coupling

25 Aminonucleosides to the Support

N-methylimidazole, tetrabutylammonium chloride, tetrabutylammonium fluoride, and imidazole are obtained from Aldrich. Bis (p-nitrophenyl) carbonate is obtained from Sigma (St. Louis, MO).

30 The supported alcohol (10 mmol) is reacted with a coupling reagent such as carbonyl diimidazole (50 mmol) in dimethylformamide (30 ml) for 3 hours at 25°C. The activated support is isolated by filtration and thoroughly washed with dimethylformamide. The support

-1c9-

is resuspended in 30 ml of dimethylformamide and treated with a selected polycarbamate polymer (50 mmol) prepared as in Example 21. After 3 hours, the supported alcohol is filtered and thoroughly washed with
5 dimethylformamide.

A selected probe is specific for a target sequence comprising residues 8441 to 8456 of the ORF-2 gene of ARV-2, the etiological agent of AIDS (Sanchez-Pescador et al, Science (1985) 227:484, is
10 synthesized by coupling the gel with the following 5'-amino nucleotides (in order of earliest introduction): C,T,G,C,T,C,C,C,A,C,C,C,C,A,T,C, where C, G, and A stand for the N-(β -(trimethylsilyl)ethoxycarbonyl) protected-
15 5'-amino-2',5'-dideoxy cytidine, -guanosine, and adenosine, respectively, and T stands for 5'-amino-2',5'-dideoxythymidine.

The supported polycarbamate (10 mmol) is suspended in acetonitrile (30 mmol) and treated with
20 tetrabutylammonium chloride (3 mmol per meq of protecting group) and potassium fluoride dihydrate (4 mmol per meq of protecting group) and heated at 50°C for 12 hours. At the end of this time water (30 ml) is added and the supported probe is thoroughly washed with
25 water. The protecting group may also be removed with tetrabutylammonium fluoride in tetrahydrofuran (2 mmol per meq of protecting group) under the same conditions.

Example 28

30 Protection of the Amino Group as the BOC-derivative
4-(N-tert-butoxycarbonyl-N-methylamino)-butyric Acid
4-(Methylamino)-butyric acid is obtained from Aldrich. Di-tert-butyl dicarbonate is obtained from Pierce (Rockford, IL).

-110-

4-(methylamino)-butyric acid (10 mmol) is dissolved in dioxane/water (30 ml, 2/1) and 1 N NaOH (10 ml) is added. The solution is cooled to 0°C and di-tert-butyl carbonate (11 mmol) is added with stirring. After 30 minutes at 25°C, the dioxane is removed under reduced pressure and the pH of the solution is adjusted to pH-2.5 by the addition of potassium bisulfate. The aqueous phase is thoroughly extracted with ethyl acetate and the organic layers combined and dried over sodium sulfate. Removal of the solvents under reduced pressure gives the free acid which is purified by recrystallization from chloroform/hexane, or by chromatography on silica gel using chloroform/methanol mixtures.

15

Example 29

Introduction of the Terminal Dimethylamino Group and General Procedure for the Activation of the Acid by Conversion to the Imidazolide and General Procedure for Coupling with an Amine

20

N,N'-carbonyl diimidazole is obtained from Aldrich.

A solution of the BOC-protected amino acid (or oligopeptide acid, 1 mmol) is treated with carbonyl diimidazole (1 mmol) at -20°C for 6 hours. At this time, a solution of dimethylamine (excess) or oligopeptide amine (1 mmol) prepared as in Example 30, in DMF (1 ml) is added at -20°C and the reaction then stirred at 25°C for 12 hours. The solvent is removed by reduced pressure and the residue is chromatographed on silica gel using methanol/chloroform to give N,N-dimethyl 4-(N-tert-butoxycarbonyl-N-methylamino)-butyramide.

-111-

Example 30

General Procedure for the Removal of the
BOC-protecting Group of
N,N-Dimethyl 4-(methylamino)-butyramide

5 Trifluoroacetic acid is obtained from Aldrich.
N,N-Dimethyl 4-(N-tert-butoxycarbonyl-N-methyl-
amino)-butyramide (of BOC-protected oligopeptide, 1
mmol) (Example XV) is dissolved in trifluoroacetic acid
(5 ml) and stirred for 1 hour at 25°C. The solvent is
10 removed and the residue is partitioned between 1 N
NaOH/saturated NaCl (1/10) and chloroform. The aqueous
phase was thoroughly extracted with chloroform and the
combined organic layers were dried over sodium sulfate
and evaporated under reduced pressure to give the free
15 amine. This could be used directly for further coupling
reactions, or can be purified on silica gel using
methanol/chloroform mixtures containing 1% triethylamine.

Using the coupling procedure and the BOC
deprotection sequence, polyamides of various lengths may
20 be prepared. For example, reaction of
4-(N-tert-butoxycarbonyl-N-methylamino)-butyryl
imidazolide with N,N-dimethyl 4-(methylamino)-butyramide
produces the dimeric monoamide. Removal of the BOC
group and coupling with another equivalent of the
25 imidazolide produces the trimeric diamide, the process
being repeated until the desired length is achieved.

Alternatively, 4-(N-tert-butoxycarbonyl-N-
methylamino)-butyryl imidazolide is reacted with
4-(methylamino)-butyric acid and the resulting dimeric
30 acid is activated with N,N-carbonyl diimidazole and
coupled with free amino oligoamides.

-112-

Example 31

General Procedure for the Reduction of
the Amide Linkages to Amines

AG-50 and Dowex-50W are obtained from Bio-Rad
5 (Richmond, CA).

The oligomeric polyamide to be reduced is treated with trifluoroacetic acid as in the general procedure in order to remove the BOC group. After isolation and purification, the free amine (1 mmol) in
10 tetrahydrofuran (1 ml) is added dropwise to a solution of borane (2 mmol per amide residue) in tetrahydrofuran (3 ml) at 25°C. The colorless solution is refluxed for 1 hour, cooled to 0°C, and treated dropwise with 6 N HCl (1ml). After all evolution of gas has ceased, the
15 solution is evaporated under reduced pressure to remove the tetrahydrofuran, and the remaining aqueous solution is applied to an AG-50 ion exchange resin and purified by washing the column of water (10 ml) and eluting the polyamine with a buffer comprised of sodium acetate (0.1-2.0 M) and sodium chloride (0.1-2.0 M) at pH 5.
20 After collection and evaporation of the fractions containing the desired product, the residue is dissolved in 1 N HCl (4 ml) and applied to a Dowex 50W ion exchange column. After washing with water, and then 2 M
25 HCl, the product is recovered as the hydrochloride by elution with 6 N HCl and removal of the solvent under reduced pressure.

The primary amino group of the polyamine is protected as the BOC-derivative and converted to the
30 ammonium salt using methyl iodide as per Example 33.

-113-

Example 33

General Procedure for the Incorporation of
a Terminal Primary Amino Group into the Polyamine

- 4-aminobutyric acid is converted to the
5 BOC-derivative. This is reacted with carbonyl
diimidazole as in Example 28 and treated with the
dimeric amide from Example 29. Cleavage of the
BOC-group and reduction as in Example 31 produced the
polyamine.
- 10 The primary amino group of the polyamine is
protected as the BOC-derivative as in the general
procedure and converted into the ammonium salt using
methyl iodide as per Example 33.

15

Example 33

General Method for the Conversion of the Polyamine
to the Poly (quaternary ammonium) Salt (3-aminopropyl)-
dimethyl-(3-(5'-dimethylamino-1-naphthalene
sulfonylamino)-propyl)-ammonium chloride

- 20 Methyl iodide and ethyldiisopropylamine are
obtained from Aldrich.
- To a solution of bis-(3-aminopropyl)
methylaniline (1 mmol) in dioxane/water (3 ml, 2/1) is
added 1 N NaOH (1 ml). With stirring, at 0°C, is added
25 di-tert-butyl dicarbonate (1.1 mmol) and the mixture is
stirred at 25°C for 30 minutes. The basic solution is
thoroughly extracted with chloroform and the combined
organic layers are dried over sodium sulfate and
evaporated. The product is dried by evaporation from
30 anhydrous dimethylformamide (5 ml). The residue is
dissolved in DMF and the solution treated with methyl
iodide (12 mmol) at 25°C for 1 hour. The solvent is
evaporated and the residue is dissolved in trifluoro-
acetic acid (5 ml). After 1 hour, the solvent is

-114-

evaporated and the residue dissolved in pyridine (5 ml). To this solution is added ethyldiisopropylamine (2 mmol per mmol of primary, secondary, and tertiary amine function) and the dansyl group is introduced by
5 treatment of the solution with 5-dimethylamino-naphthalene-sulfonyl chloride (0.9 mmol) (obtained as in Example XX) at 0°C, then allowing the mixture to stand overnight at 4°C. The reaction product is purified as in the previous paragraph by ion exchange
10 chromatography, and isolated as the hydrochloride salt.

Alternatively, the dansylated reporter may be treated directly with methyl iodide in dimethylformamide and purified by ion exchange chromatography, as above.

15

Example 34

General Method for the Introduction of the Fluorophore

5-Dimethylamino-1-naphthalene-sulfonyl chloride is obtained from Aldrich.

To a solution of a starting polyamine (1 mmol) in pyridine (5 ml) at 0°C is added 5-dimethylamino-1-naphthalene-sulfonyl chloride (0.85 mmol) and the mixture is stirred overnight at 4°C. The pyridine is then removed at 25°C under reduced pressure and the residue dissolved in 1 N HCl (5 ml) and applied to an AG-50W ion exchange column. After washing with water (10 ml), the product is eluted with a buffer comprised of sodium acetate (0.1-2.0 M) and sodium chloride (0.1-2.0 M) at pH 5. After collecting and concentrating the fractions containing the product, the residue is dissolved in water (10 ml) and applied to a Dowex 50-W (Bio-Rad) ion exchange column and washed with water (10 ml), 0.5 N HCl (5 ml), and finally the product is eluted with 6 N HCl. The hydrochloride salt of the product is

-115-

obtained by removal of the solvent under reduced pressure.

Example 35

5 Preparation of Diagnostic Reagent for
Detection of Herpes Simplex, Types I and II

The 16-base sequence at positions 462 to 477 of the 2gD gene of Herpes simplex virus, types I and II, 5'-GCGGGGCTGCGTCGG-3', comprises the selected target 10 sequence (Lasky & Downbenko, DNA (1984) 3:23). A complementary reagent polymer composed of alternating methylphosphonate/phosphodiester linkages is constructed substantially according to the methods of Examples 23 and 24.

15 The polymer is converted to the 5'-O-(6-amino-hexyl)-oligonucleotide analog and coupled through the aminohexyl spacer arm to an Affi-Gel 10 solid support material, by conventional coupling methods.

The melting temperature of the polymer/analyte 20 duplex is determined using a synthetic oligonucleotide having the 5'-GCGGGGCTGCGTCGG-3' target sequence. This target sequence, which is purchased, or constructed by conventional methods, is mixed with a substantially equimolar amount of the polymer (before polymer 25 attachment to the solid support) in annealing buffer (10 mM EDTA, 100 mM sodium phosphate, pH 7.2). This solution is heated to 90°C and slowly cooled to room temperature to effect annealing. The temperature is then slowly raised and absorbance is recorded as a 30 function of the temperature. The melting temperature (T_m) is taken as the temperature at which half the total absorbance change has occurred.

-116-

Example 36

Detection of Herpes Simplex, Types I and II

An analyte sample, taken as a skin scrape of an infected area, is suspended in 0.1 ml of EDTA-detergent
5 solution (10 mM EDTA, 1% w/v sodium dodecyl sulfate, pH to 7.0), homogenized briefly in a micro tissue grinder (Kontes #K-885470) and the homogenate filtered centrifugally in a microfilter (UWR Scientific #28151-807). One-half ml of 4.5 M sodium trichloroacetate is added,
10 followed in a few seconds by 0.6 ml of ethanol. This preparation is placed on ice for 30 min and then centrifuged for 5 min at 10,000 g. The supernatant is carefully decanted and discarded and the tube is gently rinsed with aqueous 80% ethanol. The pelleted material
15 (often not visible) is resuspended in 0.05 ml of annealing buffer (10 mM EDTA, 100 mM sodium phosphate, pH 7.2) and added to an appropriate amount of diagnostic reagent from Example XXI (estimated reagent polymer/
analyte molar ratio > 100). Annealing is carried out
20 at a temperature 8°C below the T_m of the polymer/target duplex (predetermined as described in Example 35) for 30 min and then the diagnostic reagent is washed three times with 2 ml volumes of annealing buffer. This washing is conveniently carried out centrifugally in a
25 microfilter. After washing, the diagnostic reagent is suspended in 0.2 ml of reporter solution containing 1 mg of the fluorescent-diquaternary ammonium reporter, whose synthesis is described in Example 34. The reporter solution contains only NaCl at a suitable concentration,
30 predetermined as described above. The diagnostic reagent is next washed three times with 2 ml volumes of reporter-free binding solution. Finally, reporter is eluted from the diagnostic reagent with 0.1 ml of 2 M NaCl and the elutant assessed for fluorescence in a

-117-

spectrofluorometer. The fluorescence from a control sample lacking analyte is subtracted to provide a quantitative measure proportional to the analyte present in the initial sample.

5

Example 37
Preparation of Diagnostic Reagent
for Detection of the AIDS Virus

The 16-base sequence at positions 3441-8456 of
10 the ORF-2 gene of AIDS-associated retrovirus (ARV-2),
5'-GATGGGTGGAGCAG-3', comprises the selected target
sequence (Sanchez-Pescador, et al, Science (1985)
227:484). A complementary polymer having carbamate-
linked subunits is constructed substantially according
15 to methods detailed in Example 21. Briefly, the
2'deoxyribonucleosides dA, dC, and dG are protected as
in Example X. These protected nucleosides plus
thymidine are then converted to their 5' amino
derivatives. Polymeric support is then prepared as in
20 Example 25 or 26, and subunits are linked sequentially
to this support by the method described in those
examples, to give a support-bound protected polymer
having the sequence: Support---CTGCTCCCACCCCATC-3'. In
the final step the base-protective groups are removed to
25 give the desired carbamate-linked diagnostic reagent.

The melting temperature of the polymer/analyte
is determined as follows. An RNA transcript is prepared
from single-stranded polynucleotide containing a
sequence complementary to the target sequence. This
30 target-containing RNA is suspended in annealing buffer
(10 mM EDTA, 100 mM sodium phosphate, pH 7.0) and added
to the above diagnostic reagent. The mixture is warmed
to 90°C and slowly cooled to room temperature to effect
annealing. Subsequently, the diagnostic reagent is

I 18-


placed in a small water-jacketed chromatography column through which annealing buffer is slowly pumped. The temperature is slowly raised while monitoring the effluent for released RNA. The release temperature (T_r) 5 is the temperature at which the RNA is eluted from the column. This T_r value often differs by one to a few degrees C from the corresponding T_m determined by the hyperchromic shift method described in Example XXI.

10

Example 38

Preparation of Enzymatic Reporter for Use
in Systems Employing Uncharged Diagnostic Reagents

A polycationic tail having a primary amine at one terminus is prepared as described in Examples XIV-XVIII, giving the structure:



20 One mmole of this product is reacted for 24 hr at room temperature in the dark with an excess of 4-fluoro-3-

In low light conditions the solvent is removed under reduced pressure and the solid is triturated with hexane to remove unreacted phenylazide. The solid is next suspended in 10 ml of 0.1 M NaCl and cacodylic acid is added to lower the pH to 7.2. Next, 5 mg of alkaline phosphatase (Sigma Chem Co., #P5778) is added to 1 ml of the foregoing tail solution and illuminated for 1 hr with a high flux of 366 nm light. The resulting reporter is dialyzed for 18 hr against a large volume of buffer (0.1 M NaCl, 0.05 M sodium cacodylate, pH 7.0) to remove cationic tail not linked to the enzyme. Bovine serum albumin (1% w/v) and sodium azide (0.02% w/v) are added to stabilize the enzymatic moiety of this

-119-

tetracationic reporter. Storage of this reporter solution is at 4°C in the dark.

Example 39

Detection of AIDS Virus

5 Five ml of blood suspected of containing the AIDS virus is centrifuged and 2 ml of the cell-free serum is added to 8 ml of 4.5 M sodium trichloroacetate containing 0.1 mg polyadenylic acid (Sigma Chem Co 10 #P9403). After a few seconds 10 ml of ethanol is added and the preparation chilled for 30 min in an ice bath and then centrifuged for 5 min at 10,000 g. The supernatant is carefully decanted and discarded. The pelleted nucleic acid (often not visible) is washed with 15 aqueous 80% ethanol, drained well, and resuspended in 0.1 ml of annealing buffer (10 mM EDTA, 100 mM sodium phosphate, pH 7.2) and added to an appropriate amount of diagnostic reagent from Example 37 (estimated polymer/target molar ratio > 100). Annealing is carried out at 20 a temperature 7°C below the Tr of the polymer/target duplex (predetermined as in Example 37) for one hr and then the diagnostic reagent is washed three times with 2 ml volumes of annealing buffer. This washing is conveniently carried out centrifugally in a microfilter.

25 After washing, the diagnostic reagent is suspended in 0.2 ml of an enzymatic-tetracationic reporter solution prepared as in Example 38. After 30 sec the diagnostic reagent is washed three times with 2 ml volumes of reporter-free binding solution.

30 Thereafter, the diagnostic reagent is suspended in developing solution (15 mM p-nitrophenyl phosphate, 0.5 mM MgCl₂, 1.0 M diethanolamine, pH 9.8) and incubated for 3 hr at 37°C. Reporter-generated p-nitrophenol is quantitated spectrophotometrically. Corresponding

-120-

absorbance from a control sample lacking analyte is subtracted to provide a quantitative measure proportional to the analyte present in the initial sample.

5

While the invention has been described with reference to particular embodiments, it will be appreciated that various changes and modifications can be made without departing from the invention. For example, the diagnostic reagent may include multiple species of support-bound polymers, each specie designed to bind to a different selected target sequence in polynucleotide strands from different analytes, or the diagnostic reagent may include two species of support-bound polymers, with each specie designed to bind to a different complementary strand of a duplex analyte. These multi-specie reagents offer the potential of detecting more than one analyte in a diagnostic test, or of doubling the sensitivity of detection of a single duplex analyte.

25

30

-121-

WHAT IS CLAIMED IS:

1. A diagnostic reagent for use in detection
of a single-stranded polynucleotide analyte containing a
5 selected target sequence of bases, said reagent
comprising

a solid support, and
attached to the solid support, a plurality of
polymer molecules, each composed of a sequence of base
10 complementary recognition moieties adapted to hydrogen
bond to corresponding, in-sequence bases in such target
sequence, under selected binding conditions, and an
unbranched, substantially stereoregular backbone (1)
supporting the recognition moieties at positions which
15 allow hydrogen bonding between the recognition moieties
and the corresponding in-sequence bases in the target
sequence, and (2) having a backbone charge density which
is substantially less than that of the analyte under
such selected conditions.

20

2. The diagnostic reagent of claim 1, wherein
the polymer molecules are non-homopolymeric and
substantially stereoregular, and have the form:

25 R₁ R₂ R₃ . . . R_n
 | | | |
 B ~ B ~ B ~ . . . B,


where:

(a) where R₁-R_n are recognition moieties
selected from purine, purine-like, pyrimidine, and
30 pyrimidine like heterocycles effective to bind by
Watson/Crick pairing to corresponding, in-sequence bases
in the target sequence;

-122-


- (b) n is such that the total number of Watson/Crick hydrogen bonds formed between a polymer molecule and target sequence is at least about 15;
- 5 (c) the backbone moiety length ranges from 5 to 7 atoms if the backbone moieties have a cyclic structure, and 4 to 6 atoms if the backbone moieties have an acyclic structure; and
- 10 (d) the backbone moieties support the recognition moieties at positions which allow Watson/Crick base pairing between the recognition moieties and the corresponding, in-sequence bases of the target sequences.

3. The composition of claim 2, wherein the
 15 recognition moieties are selected from the following group:



where X=F, Cl, Br, or I.

-123-




10


4. The composition of claim 2, wherein B is a cyclic moiety and B ~ B are backbone moieties joined predominantly by chemically stable, uncharged, achiral linkages having one of the following forms:

15

20



25



30


where Y = O, S and E = $\begin{array}{c} \text{O} \\ \parallel \\ \text{C} \end{array}$ or $\begin{array}{c} \text{O} \\ \parallel \\ \text{S} \\ \downarrow \\ \text{O} \end{array}$

-124-


5. The composition of claim 2, wherein B is an acyclic moiety and B ~ B are backbone moieties joined predominantly by chemically stable, uncharged, achiral linkages having one of the following forms:

5

10



15



20

6. The reagent of claim 2, wherein the backbone is composed of a series of subunit backbone moieties joined by a sequence of negatively charged achiral linkages alternating with one or more uncharged stereoisomerically defined chiral linkages.

25

7. The reagent of claim 6, wherein the backbone moieties are joined by a sequence of phosphodiester bonds alternating with one or more stereoisomerically defined methylphosphonate linkages.

30

8. A diagnostic system for determination of a single-stranded polynucleotide analyte containing a selected target sequence of bases, said system comprising


-125-

a diagnostic reagent composed of a solid support and, attached to the support, multiple polymers, each composed of a sequence of base-complementary recognition moieties adapted to hydrogen bond to 5 corresponding, in-sequence bases in the target sequence, under selected binding conditions, and an unbranched, substantially stereoregular backbone (1) supporting the recognition moieties at positions which allow hydrogen bonding between the moieties and the corresponding 10 in-sequence bases in the selected target sequence, and (2) having a backbone charge density which is substantially less than that of the analyte, under such selected conditions, and

molecules of a reporter which is composed of an 15 oligocationic tail adapted to bind electrostatically to the charged backbone of the polynucleotide analyte under preselected conditions in which the tail does not bind to the less densely charged or uncharged backbone of said polymers, and attached to the tail, one or more 20 reporter groups adapted to produce a signal by which the presence of the reporter can be detected.

9. The system of claim 8, wherein the tail in the reporter contains positive groups at intervals whose 25 spacing corresponds approximately to the spacing between adjacent phosphate groups in the backbone of the polynucleotide analyte.

, 10. The system of claim 9, wherein the tail 30 contains an oligocationic portion having the formula:



-126-

where $n = 2-5$, $m > 0$, and each $R_1 - R_5 = H$ or alkyl group.

11. The system of claim 10, wherein the reporter group in the reporter includes one or more fluorescent, chromophore, enzyme, or radioisotope groups.

12. A method for determination of a polynucleotide analyte containing a selected target base sequence, said method comprising

providing a diagnostic reagent composed of a solid support and, attached to the support, a plurality of polymer molecules, each composed of a sequence of base-complementary recognition moieties adapted to provide hydrogen bond to corresponding, in-sequence bases in the target sequence, under selected binding conditions and an unbranched, substantially stereoregular backbone (1) supporting the recognition moieties at positions which allow hydrogen bonding between the moieties and the corresponding in-sequence bases in the target sequence, and (2) having a backbone charge density which is substantially less than that of the analyte under such selected conditions,

mixing the reagent and an analyte-containing sample under such selected conditions, to produce sequence-specific binding of the analyte to the reagent polymers,

providing a reporter composed of an oligocationic tail adapted to bind to the charged backbone of the polynucleotide analyte, under preselected conditions at which the tail does not bind to the less densely charged or uncharged backbone of such polymers, and attached to the oligocationic tail, one or more reporter groups

-127-

adapted to produce a signal by which the presence of the reporter can be determined,

adding the reporter to the reagent under such preselected conditions,

5 separating the reagent from unbound material before or after adding the reporter, or both, and determining the reporter signal of analyte-associated reporter.

10 13. The method of claim 12, for use in determination of a duplex nucleic acid analyte, wherein said mixing is performed at a selected ionic strength of less than about 0.2 M monovalent cation, in the presence of a divalent cation chelating agent and at a temperature 15 above the melting temperature of such duplex analyte.

14. The method of claim 12, which further includes establishing such preselected condition as the highest salt concentration at which adequate binding of 20 reporter to the reagent-bound polynucleotide, at a given temperature, occurs.

15. A reporter for use in detecting a polynucleotide analyte, under preselected binding 25 conditions, comprising
an oligocationic tail containing two or more cationic groups which are spaced for binding to negative charges on the sugar-phosphate backbone of the polynucleotide, under such binding conditions, and
30 one or more reporter groups attached to the tail for producing a signal by which the presence of the reporter can be detected.


-128-

16. The reporter of claim 15, wherein the cationic groups in the reporter tail are spaced for binding to consecutive negative charges in such sugar-phosphate backbone.

5

17. The reagent of claim 16, wherein the tail contains an oligocationic portion having the general formula:

10



where $n = 2-5$, $m > 0$, and each $\text{R}_1-\text{R}_5 = \text{H}$ or an alkyl group.

15

18. The reporter of claim 15, wherein the reported group includes one or more fluorescent, enzyme, radioactive, chromophoric, or radioisotope group.

20

25

30

1/10

5












FIG. 1




10



15




20









X = F, Cl, Br, I

FIG. 2

25




30




2/10

5



10



15







FIG. 3

20



25



30

FIG. 4

3/10




FIG. 5A




FIG. 5B

4/10




FIG. 8






Figure 9

DMT. B_1 , B_1' , B_2 , B_2' , CE, H_1 , PCP. H_2 defined as in
Figure 3 and 4.
a = triethylamine/pyridine/water
b = benzeneenesulfonic acid/methanol/chloroform
c = mesitylenesulfonyl tetraiodide



5/10


5



10

FIG. 7A


15



20

FIG. 7B

25




30

FIG. 7C

6/10

5

10




a




15

b



c

20



25

$\text{O}-\text{CH}_2\text{NH}_2$ = aminomethylpolystyrene.


a = succinic anhydride

30 b = di(succinimido)carbonate

c = 6-aminohexanol

Figure 10

7/10



25

BOC = tert-butoxycarbonyl

a = di-tert-butyl carbonate

b = carbonyl diimidazole

c = dimethylamine

30 d = trifluoroacetic acid

e = borane-tetrahydrofuran

Figure 11

8/10








Figure 12



- a = di-tert-butyl dicarbonate
 b = methyl iodide
 c = trifluoroacetic acid

Figure 13

9/10



a = dansyl chloride

b = di-tert-butyl-dicarbonate

c = methyl iodide

30 d = trifluoroacetic acid

Figure 15




Figure 16

INTERNATIONAL SEARCH REPORT

International Application No. PCT/US86/00545

I. CLASSIFICATION OF SUBJECT MATTER (if several classification symbols apply, indicate all) *

According to International Patent Classification (IPC) or to both National Classification and IPC

INT. CL. 4 : C12Q 1/68; C12P 19/34; C12N 15/00

U.S. CL. : 435/6,91; 935/78

II. FIELDS SEARCHED

Minimum Documentation Searched *

Classification System	Classification Symbols
U.S.	435/6,68,91,188,810
	435/94,501,518,808
	935/3,6,78

Documentation Searched other than Minimum Documentation
to the Extent that such Documents are Included in the Fields Searched *Computer Search: Chemical Abstracts 1967-1986;
Biosis 1977-1986; Derwent (WPI, WPIL, Biotechnology)

III. DOCUMENTS CONSIDERED TO BE RELEVANT **

Category *	Citation of Document, * with indication, where appropriate, of the relevant passages **	Relevant to Claim No. **
P, Y	Biochemistry, Volume 24, No. 22 issued August, 1985, A. Murakami et al, "Characterization of Sequence-Specific Oligo- deoxyribonucleoside Methyl- phosphonates and Their Interaction with Rabbit Globin mRNA," see pages 4045 and 4046.	1-12
Y	US,A, 4,395,486 (Wilson) 26 July, 1983, see column 3, lines 50-61.	13,14
Y	Nucleic Acids Research, Volume 12, No. 8, issued April 25, 1984, M. Renz et al, "A colorimetric method for DNA hybridization", see page 3435.	8-12,15- 18

* Special categories of cited documents: **

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

IV. CERTIFICATION

Date of the Actual Completion of the International Search *

05 June 1986

Date of Mailing of this International Search Report *

19 JUN 1986

International Searching Authority *

ISA/US

Signature of Authorized Officer **

Jeremy M. Jay

III. DOCUMENTS CONSIDERED TO BE RELEVANT (CONTINUED FROM THE SECOND SHEET)

Category *	Citation of Document, ¹⁶ with indication, where appropriate, of the relevant passages ¹⁷	Relevant to Claim No ¹⁸
X Y	Biochemistry, Volume 20, No. 7, issued March 31, 1981, P.S. Miller et al, "Biochemical and Biological Effects of Nonionic Nucleic Acid Methylphosphonates", see pages 1878 and 1879.	1 2-12
X Y	US,A, 4,507,433 (Miller) 26 March 1985 see column 1, lines 32-37.	1 2-12
X Y	Journal of Biological Chemistry, Volume 255, No. 20, issued October 25, 1980, P.S. Miller et al, "Oligothymidylate Analogues Having Stereoregular, Alternating Methylphos- phonate/Phosphodiester Backbones", see page 9659.	1 2-12
Y	US, A, 4,362,531 (de Steenwinkel) 07 December 1982, see column 3, lines 50-64.	13,14
Y	US, A, 4,430,496 (Abbott) 07 February 1984, see column 6, lines 37-40.	8-12,15-18